WO2023138317A1 - 具有ripk1抑制活性的化合物、其制备方法及其用途 - Google Patents
具有ripk1抑制活性的化合物、其制备方法及其用途 Download PDFInfo
- Publication number
- WO2023138317A1 WO2023138317A1 PCT/CN2022/142343 CN2022142343W WO2023138317A1 WO 2023138317 A1 WO2023138317 A1 WO 2023138317A1 CN 2022142343 W CN2022142343 W CN 2022142343W WO 2023138317 A1 WO2023138317 A1 WO 2023138317A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- aryl
- membered heteroaryl
- membered
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 title abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 201000010099 disease Diseases 0.000 claims abstract description 35
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims abstract description 21
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims abstract description 21
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 10
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 137
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 72
- 125000000623 heterocyclic group Chemical group 0.000 claims description 71
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 55
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 42
- -1 cyano, amino Chemical group 0.000 claims description 30
- 125000004149 thio group Chemical group *S* 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 17
- 229910052805 deuterium Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 230000003287 optical effect Effects 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims description 16
- 239000000651 prodrug Substances 0.000 claims description 15
- 229940002612 prodrug Drugs 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 108091000080 Phosphotransferase Proteins 0.000 claims description 12
- 102000020233 phosphotransferase Human genes 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 10
- 206010028851 Necrosis Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 230000017074 necrotic cell death Effects 0.000 claims description 9
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 6
- 206010063837 Reperfusion injury Diseases 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 150000004677 hydrates Chemical class 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 206010033645 Pancreatitis Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 230000002207 retinal effect Effects 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 4
- 108090000426 Caspase-1 Proteins 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 4
- 206010057430 Retinal injury Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 4
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 4
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 208000015872 Gaucher disease Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000003221 Lysosomal acid lipase deficiency Diseases 0.000 claims description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 3
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010061481 Renal injury Diseases 0.000 claims description 3
- 206010038848 Retinal detachment Diseases 0.000 claims description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 108090000848 Ubiquitin Proteins 0.000 claims description 3
- 102000044159 Ubiquitin Human genes 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 208000026589 Wolman disease Diseases 0.000 claims description 3
- 201000003229 acute pancreatitis Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000004264 retinal detachment Effects 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- 208000036443 AIPL1-related retinopathy Diseases 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims description 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 2
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 208000025721 COVID-19 Diseases 0.000 claims description 2
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 206010011777 Cystinosis Diseases 0.000 claims description 2
- 208000011518 Danon disease Diseases 0.000 claims description 2
- 206010012218 Delirium Diseases 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 208000013171 Fahr disease Diseases 0.000 claims description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 2
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 claims description 2
- 208000033149 Farber disease Diseases 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- 201000008892 GM1 Gangliosidosis Diseases 0.000 claims description 2
- 208000001905 GM2 Gangliosidoses Diseases 0.000 claims description 2
- 201000008905 GM2 gangliosidosis Diseases 0.000 claims description 2
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 206010064571 Gene mutation Diseases 0.000 claims description 2
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 2
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 2
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 claims description 2
- 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 claims description 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 claims description 2
- 206010021024 Hypolipidaemia Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims description 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000028226 Krabbe disease Diseases 0.000 claims description 2
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims description 2
- 208000001344 Macular Edema Diseases 0.000 claims description 2
- 206010025415 Macular oedema Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims description 2
- 208000012583 Menkes disease Diseases 0.000 claims description 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000008955 Mucolipidoses Diseases 0.000 claims description 2
- 206010072927 Mucolipidosis type I Diseases 0.000 claims description 2
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 206010062207 Mycobacterial infection Diseases 0.000 claims description 2
- 108010057466 NF-kappa B Proteins 0.000 claims description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010051606 Necrotising colitis Diseases 0.000 claims description 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000014245 Ocular vascular disease Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 2
- 206010031264 Osteonecrosis Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 108700005075 Regulator Genes Proteins 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000002367 Retinal Perforations Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 208000014139 Retinal vascular disease Diseases 0.000 claims description 2
- 208000021811 Sandhoff disease Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000005400 Synovial Cyst Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000034799 Tauopathies Diseases 0.000 claims description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 2
- 206010043189 Telangiectasia Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims description 2
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 2
- 206010046392 Ureteric cancer Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000014769 Usher Syndromes Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 208000018839 Wilson disease Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 231100000836 acute liver failure Toxicity 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 150000001345 alkine derivatives Chemical class 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 230000022743 cholesterol storage Effects 0.000 claims description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000031214 ciliopathy Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 201000006754 cone-rod dystrophy Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 210000000750 endocrine system Anatomy 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000008049 fucosidosis Diseases 0.000 claims description 2
- 210000000609 ganglia Anatomy 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 2
- 201000008977 glycoproteinosis Diseases 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 208000002557 hidradenitis Diseases 0.000 claims description 2
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 230000009524 hypoxic brain injury Effects 0.000 claims description 2
- 230000000642 iatrogenic effect Effects 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 208000037906 ischaemic injury Diseases 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000037806 kidney injury Diseases 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
- 208000029233 macular holes Diseases 0.000 claims description 2
- 201000010230 macular retinal edema Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 208000012268 mitochondrial disease Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 208000020911 optic nerve disease Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000012237 paracetamol poisoning Diseases 0.000 claims description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims description 2
- 230000003239 periodontal effect Effects 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 2
- 108010040003 polyglutamine Proteins 0.000 claims description 2
- 229920000155 polyglutamine Polymers 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 201000002241 progressive bulbar palsy Diseases 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 201000000196 pseudobulbar palsy Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 208000011985 sialidosis Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 230000000391 smoking effect Effects 0.000 claims description 2
- 208000037959 spinal tumor Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 208000009056 telangiectasis Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- WCYWZMWISLQXQU-FIBGUPNXSA-N trideuteriomethane Chemical compound [2H][C]([2H])[2H] WCYWZMWISLQXQU-FIBGUPNXSA-N 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 2
- 230000005747 tumor angiogenesis Effects 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000011294 ureter cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000033810 Choroidal dystrophy Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 101001081220 Homo sapiens RanBP-type and C3HC4-type zinc finger-containing protein 1 Proteins 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 102100027716 RanBP-type and C3HC4-type zinc finger-containing protein 1 Human genes 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000003571 choroideremia Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 abstract description 4
- 208000023589 ischemic disease Diseases 0.000 abstract description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 102000001253 Protein Kinase Human genes 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 108060006633 protein kinase Proteins 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 230000021597 necroptosis Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 150000002772 monosaccharides Chemical class 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- TXUWMXQFNYDOEZ-UHFFFAOYSA-N 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone Chemical compound O=C1N(C)C(=S)NC1CC1=CNC2=CC=CC=C12 TXUWMXQFNYDOEZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102100030013 Endoribonuclease Human genes 0.000 description 2
- 101710199605 Endoribonuclease Proteins 0.000 description 2
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- HSXZZWGNLDGWIC-UHFFFAOYSA-N 2-(2-carboxy-6-nitrophenyl)-3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1C1=C(C(O)=O)C=CC=C1[N+]([O-])=O HSXZZWGNLDGWIC-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- FGKQHXRVPDLTDF-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazepin-5-one Chemical compound O=C1NCCOC2=CC=CC=C12 FGKQHXRVPDLTDF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- LYPAFUINURXJSG-AWEZNQCLSA-N 5-benzyl-n-[(3s)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1h-1,2,4-triazole-3-carboxamide Chemical compound N([C@H]1COC2=CC=CC=C2N(C1=O)C)C(=O)C(N=1)=NNC=1CC1=CC=CC=C1 LYPAFUINURXJSG-AWEZNQCLSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101000942941 Arabidopsis thaliana DNA ligase 6 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010072039 Histidine kinase Proteins 0.000 description 1
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004902 Iron regulatory protein 2 Human genes 0.000 description 1
- 108090001028 Iron regulatory protein 2 Proteins 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 101150071716 PCSK1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000011186 acute T cell leukemia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 201000002922 basal ganglia calcification Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 208000016791 bilateral striopallidodentate calcinosis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical compound C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000003937 effect on alzheimer disease Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004806 ferroptosis Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229950008554 levamlodipine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 150000004032 porphyrins Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000006010 pyroptosis Effects 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 150000003641 trioses Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to compounds with receptor-interacting protein kinase 1 inhibitory activity, their preparation methods and uses thereof, especially the use of the series of compounds or pharmaceutical compositions containing the series of compounds and therapeutic agents for treating inflammatory diseases, ischemic diseases, neurodegenerative diseases, tumors and other diseases and diseases related to receptor-interacting protein kinase 1.
- Protein kinases are proteins (enzymes) that regulate various cellular functions by phosphorylating specific amino acids on proteins. Proteins regulate their activity and ability to bind to their chemical components through conformational changes.
- the activity of a protein kinase refers to the rate at which a kinase binds a phosphate group to a substrate, which rate can be measured by measuring the amount of substrate converted to a product over a period of time. Phosphorylation of the substrate occurs at the activation site of the protein kinase.
- protein kinases can be divided into five categories: serine/threonine protein kinases, tyrosine protein kinases, histidine protein kinases, tryptophan protein kinases and aspartyl/glutamyl protein kinases.
- serine/threonine protein kinase is a class of enzymes that can catalyze the phosphorylation of serine/threonine residues on various substrate proteins
- tyrosine kinase is a kind of protein enzyme that can catalyze the transfer of adenosine triphosphate to protein tyrosine residues.
- Pathological conditions associated with protein kinases include inflammatory diseases, immune diseases, cardiovascular diseases, and tumors, among others.
- Cell death mainly includes apoptosis, necroptosis, pyroptosis, ferroptosis, and cell death processes related to autophagy and unprogrammed necrosis.
- Necroptosis also known as programmed cell death or programmed necrosis, is a new type of cell death discovered in recent years.
- Necroptosis a highly inflammatory form of cell death that results in the release of danger-associated molecular patterns from cells, is considered an important pathological factor in a variety of degenerative and inflammatory diseases. These diseases include neurodegenerative diseases, stroke, coronary heart disease, myocardial infarction, retinal degenerative diseases, inflammatory bowel disease, kidney disease, liver disease, and various other related diseases.
- Receptor-interacting protein kinase 1 (RIPK1) and RIPK3 are homologous serine/threonine kinases, which are key elements in mediating cell necroptosis.
- RIPK1 kinase is recognized as a potential therapeutic target for necroptosis-related diseases.
- the first RIPK1 inhibitor Necrostatin-1 (Nec-1) and its analogues have shown clear curative effects on a variety of degenerative diseases, inflammation, cancer and other diseases in preclinical studies.
- Alzheimer's disease Parkinson's disease, Huntington's disease, age-related macular degeneration, etc.
- it has a protective effect on psoriasis, retinitis pigmentosa, inflammatory bowel disease, autoimmune disease, acute pancreatitis and sepsis/systemic inflammatory response syndrome induced by bombesin
- it can effectively relieve ischemic brain injury, ischemic myocardial injury, retinal ischemia/reperfusion injury, photoreceptor cell necrosis induced by retinal detachment, glaucoma, renal ischemia-reperfusion injury, and cisplatin-induced Renal injury and traumatic brain injury:
- At least partial remission of other diseases associated with RIPK1-dependent apoptosis, necrosis or cytokine production including hematological and solid organ malignancies, bacterial and viral infections (including tuberculosis, influenza, etc.) and lysosomal storage disorders (
- kinase inhibitors especially RIPK1 kinase inhibitors
- the existing inhibitors targeting necroptosis-related kinases have defects of varying degrees, such as poor selectivity, unsatisfactory in vivo inhibitory activity, poor pharmacokinetic properties, low oral bioavailability, etc., and some cannot enter the central nervous system through the blood-brain barrier.
- the object of the present invention is to provide RIPK1 kinase inhibitors.
- the first aspect of the present invention provides a compound represented by general formula (I) or its stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, tautomers or pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates or solvates thereof, and isotope-labeled compounds thereof,
- Cy 1 is selected from the following group:
- R at each occurrence is independently selected from: H, D, halogen, CD 3 , C1-C8 alkyl, halogenated C1-C8 alkyl, C1-C8 alkoxy, halogenated C1-C8 alkoxy, cyano, amino, C1-C8 alkyl substituted amino, hydroxyl, mercapto, C1-C8 alkylthio;
- Cy 2 is selected from the following groups substituted by 0-5 R 8 : C3-C14 cycloalkyl, C6-C14 membered aryl, 6-14 membered heteroaryl, or 3-14 membered heterocyclic group;
- R4 at each occurrence is independently selected from: H, D, CH3 , CD3 ;
- Each dashed line independently represents a single bond or a double bond
- Z 2 is selected from C(R z2 ) 2 , N, CR z2 ; each R z2 is independently H, halogen, hydroxyl, optionally substituted C1-C8 alkyl, or two R z2 form an optionally substituted C3-C6 carbocycle or 3-6 membered heterocycle together with the carbon atoms to which they are attached,
- R z2 , R z1 together with the carbon atoms they are connected to form an optionally substituted C3-C6 carbocycle or 3-6 membered heterocycle;
- Z 3 and Z 4 are selected from C, CH, N;
- Ring A is a C6-C14 membered aromatic ring, a 5-membered heteroaromatic ring, a 6-14 membered heteroaromatic ring, a C3-C14 carbocyclic ring or a 3-14 membered heterocyclic ring;
- n is selected from 1, 2, 3, 4;
- R 1 is independently selected from H, D, "R 7 -C ⁇ C-", R 1a at each occurrence; preferably, at least one R 1 on ring A is a substituent of "R 7 -C ⁇ C-";
- R 1a , R 7 are independently at each occurrence R 1a1 substituted by 0-5 R 1a2 ;
- R 1a1 and R 1a2 can be optionally replaced by 0-5 R 1a3 ;
- R 2 does not exist, or R 2 is in the ortho position of Z 4 , and forms an optionally substituted or unsubstituted 5-6 membered heterocyclic ring with R 3 and the atoms they are connected to;
- R 3 is selected from: H, D, CH 3 , CD 3 ;
- Y is O, S, NR y , wherein R y and R 3 form an optionally substituted 5-6 membered heterocyclic ring or a 5-6 membered heteroaromatic ring together with the atoms they are connected to;
- R 6 is selected from: CD 3 , C1-C8 alkyl, halogenated C1-C8 alkyl, C6-C14 aryl;
- R 1a1 , R 1a2 In each occurrence independently selected from the group consisting of: H, D, halogen, C1-C8 alkyl, halogenated C1-C8 alkyl, C1-C8 alkoxy, halogenated C1-C8 alkoxy, C1-C6 alkoxy substituted C1-C6 alkoxy, C2-C8 alkenyl, halogenated C2-C8 alkenyl, C2-C8 alkenyloxy, halogenated C2-C8 alkenyloxy, C2-C8 alkynyl, halogenated C2-C8 alkyne C2-C8 alkynyloxy, halogenated C2-C8 alkynyloxy, C3-C14 cycloalkyl, (C3-C14 cycloalkyl)-(C1-C8 alkyl)-, (C3-C14 cycloalkyl) oxy, (C3-C14 cycloalkyl
- At least one R 1 is R 7 -C ⁇ C-". That is, m is 1, R 1 is R 7 -C ⁇ C-"; m is 2, 3 or 4, and one R 1 is R 7 -C ⁇ C-", and other R 1 are independently selected from H, D, "R 7 -C ⁇ C-", R 1a .
- the compound represented by general formula (I) has the structure:
- the compound shown in general formula (I) has the structure shown in formula (II):
- the compound is selected from formulas (IV-1), (IV-2), (IV-4), (IV-5), (IV-6), (IV-7), (IV-9):
- Cy 3 is selected from formulas (III-1) to (III-14):
- Z 5 is selected from CR 1 or N; R 1 , m, Z 1 , R 3 are as defined above; preferably, Z 5 is selected from CH or N; when m is 1, R 1 is R 7 -C ⁇ C-; R 7 is as defined above.
- the compound is selected from formulas (V-1), (V-2), (V-3), (V-4):
- Z 5 is selected from CR 1 or N; R 1a1 , R 1 , R 3 , Z 1 , Cy 1 , Cy 2 and R 5 are as defined above.
- the compound is selected from:
- Z 5 is selected from CH or N; R 1 is a C1-C8 alkyl group; R 1a1 , R 3 , Z 1 , Cy 2 , and R 5 are as defined above.
- R 1 is independently selected from the following group at each occurrence: H, D, methyl,
- the compound is the compound listed in claim 5.
- the second aspect of the present invention provides the preparation method of the compound shown in formula (I) described in the first aspect, and the synthesis step includes at least one of Reaction Formula 1 and Reaction Formula 2:
- R 4 , R 1 , m, R 2 , R 3 , Y, Z 1 , Z 2 , Z 3 , Z 4 , dotted line, and Cy 1 are as defined above.
- the third aspect of the present invention provides a pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and one or more compounds described in the first aspect or stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, tautomers or pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates or solvates thereof, and isotope-labeled compounds thereof.
- a fourth aspect of the present invention provides a receptor-interacting protein kinase 1 (RIPK1) inhibitor, comprising one or more compounds described in the first aspect or their stereoisomers, geometric isomers, tautomers, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates or solvates thereof, or the pharmaceutical composition described in the third aspect.
- RIPK1 receptor-interacting protein kinase 1
- the fifth aspect of the present invention provides the use of the compound described in the first aspect or its stereoisomer, enantiomer, diastereoisomer, atropisomer, optical isomer, racemate, tautomer or pharmaceutically acceptable salt thereof, its prodrug, its hydrate or solvate, its isotope-labeled compound or the pharmaceutical composition described in the third aspect, characterized in that it is used for the preparation of medicines, and the medicines are used for: 1) detection and/or prevention and/or treatment of kinase-related diseases; 2) detection and/or 3) Detect and/or prevent and/or treat diseases related to ischemia and/or reperfusion injury; 4) Detect and/or prevent and/or treat degenerative diseases; 5) Detect and/or prevent and/or treat tumor-related diseases; 6) Detect and/or prevent and/or treat diseases related to cell necrosis; 7) Detect and/or prevent and/or treat diseases related to metabolism;
- the sixth aspect of the present invention provides the use of the compound described in the first aspect or its stereoisomer, enantiomer, diastereomer, atropisomer, optical isomer, racemate, tautomer or pharmaceutically acceptable salt thereof, its prodrug, its hydrate or solvate, its isotope-labeled compound, or the pharmaceutical composition described in the third aspect, characterized in that it is used to prepare a drug for detection and/or prevention and/or treatment of a disease selected from the following group:
- Systemic juvenile idiopathic arthritis, Behcet's disease, interleukin-1 converting enzyme-related febrile syndrome, sepsis, alopecia areata, allergic disease, allergic disease, hepatitis B, hepatitis C, multiple sclerosis, pulmonary sarcoidosis, pulmonary fibrosis, pneumonia, mycobacterial infection, celiac disease, Sjogren's syndrome, osteoarthritis, hidradenitis suppurativa, necrotizing enterocolitis, acute pancreatitis, spondyloarthritis, colitis, Crohn's disease, antiphosphorus Lipid syndrome, Crohn's disease, ulcerative colitis, rheumatoid arthritis, bacterial infection, influenza, chronic obstructive pulmonary disease, viral infection, sepsis, dermatitis, staphylococcal infection, autoimmune disease, systemic lupus erythematosus, systemic inflammatory response syndrome, systemic scleroderma
- the kinase inhibitor has excellent RIPK1 inhibitory activity, so it can be used to prepare pharmaceutical compositions for detection and/or prevention and/or treatment of cell death and/or related diseases.
- the inventors have completed the present invention.
- C1 - C6 means having 1, 2, 3, 4, 5 or 6 carbon atoms
- C1 - C8 means having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, and so on.
- 5-8 membered means having 5-8 ring atoms, and so on.
- Substituent refers to an atom or group that can replace a hydrogen atom in a substituent.
- substitution means that one or more hydrogen atoms on a specified group are replaced by a specified substituent.
- the specific substituents are the corresponding substituents described above, or the substituents appearing in each embodiment.
- a substituted group may have a substituent selected from a specific group at any substitutable position of the group, and the substituents may be the same or different at each position.
- Alkyl means a saturated aliphatic hydrocarbon group, which may be straight or branched.
- the alkyl groups may be independently substituted with one or more substituents described herein. Further examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 3-methylpentyl.
- Alkyl groups can be optionally substituted or unsubstituted.
- Alkenyl straight-chain or branched hydrocarbon group, wherein at least one CC is a sp 2 double bond, wherein the alkenyl group can be independently and optionally replaced by one or more substituents described in the present invention, wherein specific examples include, but are not limited to vinyl, allyl, butyl, etc. Alkenyl groups can be optionally substituted or unsubstituted.
- Alkynyl refers to a straight-chain or branched hydrocarbon group, wherein at least one C-C is an sp triple bond, wherein the alkynyl group can be independently and optionally substituted by one or more substituents described in the present invention, and specific examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, etc. Alkynyl groups can be optionally substituted or unsubstituted.
- Ring structure refers to a single or polycyclic structure. Usually two or more fragments connected to one atom in the ring structure are connected to form a closed structure, including but not limited to cycloalkane, heterocycloalkane, cyclic lactam, arene, heteroarene, ring, bridged ring, spiro ring and other structures, examples are as follows (but not limited to the following examples): cyclopropane, cyclobutane, oxetane, cyclopentane, cyclohexane, adamantane, cyclohexene, cyclooctyne, pyrazole, benzene, pyridine, 3,4-dihydro-1,4- Benzoxazepine-5(2H)-one, naphthalene, anthracene, phenanthrene, quinoline, pyrrolopyridine, pyrazolopyridine, indole
- the ring structures may be optionally substituted or unsubstituted. When it appears as a substituent, it means that one or more hydrogen atoms on a monocyclic or polycyclic ring are removed so that it can serve as a substituent for a substituted substance.
- Halogen refers to F, Cl, Br or I.
- Halo means substituted with one or more halogens.
- Aryl refers to a carbocyclic aromatic system containing one or more rings free of heteroatoms.
- the aryl group may be fused to a heteroaryl, heterocyclyl, or other ring structure. Examples include (but are not limited to) the following examples: phenyl, naphthyl, tetrahydronaphthyl, wait.
- the aryl group may be optionally substituted or unsubstituted.
- aryl group is described as "C6-C14 aryl"
- the aryl group can be optionally fused with other ring structures
- the other ring structures refer to ring structures with 3-18 ring atoms, and the other ring structures may be optionally substituted or unsubstituted.
- Heteroaryl refers to an aromatic ring structure containing one or more rings, which may contain one or more atoms selected from N, O or S. Alternatively, the aryl group may be fused to an aryl, heterocyclyl, cycloalkyl or other ring structure. Examples include (but are not limited to) the following examples: furyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, wait.
- the heteroaryl group can be optionally substituted or unsubstituted.
- heteroaryl When the heteroaryl is described as "5-14 membered heteroaryl", it means that the heteroaryl ring connected to the parent structure has 5-14 ring atoms, but the heteroaryl may be fused with other ring structures, and the other ring structures refer to ring structures with 3-18 ring atoms, and the other ring structures may be optionally substituted or unsubstituted.
- Cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent.
- the first ring structure where the cycloalkyl is directly attached to the substituent is non-aromatic.
- monocyclic cycloalkyl groups (but not limited to the following examples): cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, cyclooctynyl, etc.
- multicyclic cycloalkyl groups (but not limited to the following examples): spiro, fused and bridged cycloalkyls.
- the cycloalkyl may be fused or form a spiro with an aryl, heterocyclyl, cycloalkyl or other ring structures.
- the cycloalkyl group may be optionally substituted or unsubstituted.
- C3-C14 cycloalkyl it means that the cycloalkyl ring connected to the parent structure has 3-14 carbon atoms, but the cycloalkyl group can be fused with other ring structures or form a spiro ring.
- the other ring structures refer to ring structures with 3-18 ring atoms, and the other ring structures can be optionally substituted or unsubstituted.
- Heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic ring structure in which at least one ring atom is a heteroatom (eg, O, N, S atom, etc.). Examples include (but are not limited to) tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrrolyl, tetrahydrothienyl, piperidinyl, piperazinyl, azetidinyl, azepanyl, morpholinyl, 2-oxo-pyrrolidinyl, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl, and the like.
- the heterocyclyl ring may be fused to an aryl, heteroaryl, or cycloalkyl ring where the ring bonded to the parent structure is a heterocyclyl.
- the heterocyclyl group may be optionally substituted or unsubstituted.
- the description of the heteroalkyl group is "3-14 membered heterocyclic group” it means that the heterocyclic group connected to the parent structure has 3-14 ring atoms, but the heterocyclic group may be fused with other ring structures or form a spiro ring.
- the other ring structures refer to ring structures with 3-18 ring atoms, and the other ring structures may be optionally substituted or unsubstituted.
- Tautomer means that structural isomers with different energies can be interconverted beyond a low energy barrier.
- proton tautomers i.e., proton shifts
- proton migration such as 1H-indazole and 2H-indazole, 1H-benzo[d]imidazole and 3H-benzo[d]imidazole
- valence tautomers include interconversions through some bonded electron recombination.
- Stepoisomer refers to molecules that have atoms connected identically but arranged differently in space. For example, two compounds that contain a chiral center and have the same two-dimensional linkage, such as R-glyceraldehyde and S-glyceraldehyde, R-serine and S-serine.
- Enantiomers means stereoisomers that are real and mirror images of each other and are not superimposable. Such as R-serine and S-serine.
- Diastereoisomer means a stereoisomer whose molecules have two or more chiral centers and which are not mirror images of each other. Such as tartaric acid.
- “Atropisomer” means a group of conformational isomers of a molecule resulting from hindered rotation about a single bond. For example, the individual stereoisomers of 6,6'-dinitro-2,2'-biphenyldicarboxylic acid.
- Optical isomer refers to a compound in which two or more molecules have the same two-dimensional connection, but exhibit different optical rotation properties due to differences in configuration. Such as levamlodipine and dexamlodipine.
- Racemate refers to compounds that have the same two-dimensional connection mode but are optical isomers of each other, and when mixed together, they finally appear as substances without optical activity. than racemic amlodipine.
- amino acid acyl refers to a substituent in which the carboxyl group of an amino acid is converted into an acyl group and linked to a substituent through the acyl group.
- the amino acids include, but are not limited to, ⁇ -amino acids, ⁇ -amino acids, ⁇ -amino acids, and ⁇ -amino acids.
- Such amino acids include, but are not limited to, the following examples: glycine, alanine, valine, leucine, isoleucine, methionine (methionine), proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine, pyrrolysine, beta-alanine, and the like.
- glycosyl refers to a substituent of a monosaccharide or an oligosaccharide in the form of providing a hemiacetal hydroxyl group.
- the monosaccharides include aldoses and ketoses.
- the monosaccharides include triose, tetose, pentose, hexose and heptose.
- the oligosaccharide also known as oligosaccharide, refers to a compound containing 2-11 monosaccharides, and each monosaccharide is polymerized through glycosidic bonds.
- Examples of the monosaccharide or polysaccharide are as follows (but not limited to the following examples): erythrose, thulose, arabinose, ribose, xylose, lyxose, glucose, mannose, fructose, galactose, lactose, sucrose, maltose, ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin.
- the pharmaceutically acceptable salt of the present invention may be a salt formed by an anion and a positively charged group on the compound of formula (I).
- Suitable anions are chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, acetate, malate, tosylate, tartrate, fumarate, glutamate, glucuronate, lactate, glutarate or maleate.
- salts can be formed from cations with negatively charged groups on compounds of formula (I). Suitable cations include sodium, potassium, magnesium, calcium and ammonium, such as tetramethylammonium.
- “pharmaceutically acceptable salt” refers to the salts formed by the compound of formula (I) with an acid selected from the following group: hydrofluoric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, acetic acid, oxalic acid, sulfuric acid, nitric acid, methanesulfonic acid, sulfamic acid, salicylic acid, trifluoromethanesulfonic acid, naphthalenesulfonic acid, maleic acid, citric acid, acetic acid, lactic acid, tartaric acid, succinic acid, oxalic acid, pyruvic acid, malic acid, glutamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid acid, ethanesulfonic acid, naphthalenedisulfonic acid, malonic acid, fumaric acid, propionic acid, oxalic acid, trifluoroacetic acid, stearic acid,
- the present invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and one or more therapeutically effective doses of the compound of the present invention or its stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, tautomers or pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates or solvates thereof, and isotope-labeled compounds thereof.
- the pharmaceutical composition of the present invention comprises the compound of the present invention or a pharmacologically acceptable salt thereof within a safe and effective amount range and a pharmaceutically acceptable excipient or carrier.
- safe and effective dose refers to: the amount of the compound is sufficient to obviously improve the condition without causing severe side effects.
- the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, more preferably, 50-200 mg of the compound of the present invention per dose.
- the "one dose” is a capsule or tablet.
- “Pharmaceutically acceptable carrier” refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use, and must have sufficient purity and low enough toxicity. "Compatibility” herein means that the components of the composition can be blended with the compound of the present invention and with each other without significantly reducing the efficacy of the compound.
- Examples of pharmaceutically acceptable carrier moieties include cellulose and derivatives thereof (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyhydric alcohols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agent (such as sodium lauryl sulfate), coloring agent, flavoring agent, stabilizer, antioxidant, preservative, pyrogen-free water, etc.
- cellulose and derivatives thereof such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
- gelatin such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
- talc such as ste
- the pharmaceutical composition is injection, capsule, tablet, pill, powder or granule.
- administration methods of the compounds or pharmaceutical compositions of the present invention are not particularly limited, and representative administration methods include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
- the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and acacia; Potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slowing agents, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; In capsules, tablets and pills, the dosage form may also contain
- Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shell materials, such as enteric coatings and others well known in the art. They may contain opacifying agents and, in such compositions, the release of the active compound or compounds may be in a certain part of the alimentary canal in a delayed manner.
- coatings and shell materials such as enteric coatings and others well known in the art. They may contain opacifying agents and, in such compositions, the release of the active compound or compounds may be in a certain part of the alimentary canal in a delayed manner.
- Examples of usable embedding components are polymeric substances and waxy substances.
- the active compounds can also be in microencapsulated form, if desired, with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
- liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances and the like.
- inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide and oils
- compositions can also contain adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Suspensions in addition to the active compounds, may contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
- suspending agents for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
- compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- Suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols, and suitable mixtures thereof.
- Dosage forms for topical administration of a compound of this invention include ointments, powders, patches, sprays and inhalants.
- the active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required, if necessary.
- the compound of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds (such as antineoplastic drugs).
- other pharmaceutically acceptable compounds such as antineoplastic drugs.
- the treatment method of the present invention can be used alone or in combination with other treatment methods or drugs.
- a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage is a pharmaceutically effective dosage.
- the daily dosage is usually 1-2000 mg, preferably 5-500 mg.
- factors such as the route of administration and the health status of the patient should also be considered for the specific dosage, which are within the skill of skilled physicians.
- HATU N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)urea hexafluorophosphate
- DMF N,N-Dimethylformamide
- TEA Triethylamine
- DIPEA Diisopropylethylamine
- DMAC N,N-dimethylacetamide
- Pd(dppf)Cl 2 [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride
- NBS N-bromosuccinimide
- NMP N-methylpyrrolidone
- Pd(PPh 3 ) 4 tetrakistriphenylphosphine palladium
- DPPA diphenylphosphoryl azide
- 4-DMAP 4-dimethylaminopyridine
- NaBH 3 CN sodium cyanoborohydride
- PTSA p-toluenesulfonic acid
- MeOH methanol
- EtOH ethanol
- Boc 2 O di-tert-butyl dicarbonate
- DMSO dimethyl sulfoxide
- Pd(dppf)Cl 2 [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride
- reaction mixture was poured into water, extracted three times with ethyl acetate, the ethyl acetate layers were combined, washed five times with saturated sodium chloride, and finally the organic phase was dried over anhydrous sodium sulfate and concentrated, and purified by preparative thin layer chromatography to obtain I-1, yield: 47 mg, yield: 92.1%.
- + indicates that the IC 50 is less than ( ⁇ ) 0.1 ⁇ M. It can be seen from Table 1 that the compound of the present invention has obvious inhibitory effect on RIPK1 enzyme.
- I2.1 cell line the FADD mutant of human acute T-cell leukemia Jurkat cells, the FADD protein in the cells is missing, and TNF ⁇ alone can induce programmed necrosis in cells. It was detected by CCK-8 cell counting kit (Dojindo).
- I2.1 cells in the logarithmic growth phase were inoculated into 96-well culture plates at an appropriate density. After culturing overnight, compounds of different concentrations were added first, and 20 ng/mL of TNF ⁇ was added to stimulate one hour later. Control wells without compounds and stimulating factors (positive control) and control wells without compounds and stimulating factors (negative control) were set. After the compound acted on the cells for 24 hours, the effect of the compound on the cell proliferation was detected using the CCK-8 cell counting kit (Dojindo). Add 10 ⁇ L of CCK-8 reagent to each well, place it in a 37°C incubator for 2-4 hours, and read it with a full-wavelength microplate microplate reader SpectraMax190, with a wavelength of 450nm.
- the recovery rate (%) of the compound to programmed cell necrosis was calculated by the following formula:
- IC50 values were calculated using GraphPad Prism software.
Abstract
本发明公开了一种具有RIPK1抑制活性的化合物、其制备方法及其用途,该化合物结构如通式I所示,各取代基的定义如说明书和权利要求书所述。本发明的化合物,能够用于治疗与受体相互作用蛋白激酶1相关的炎症性疾病、缺血性疾病、神经退行性疾病、肿瘤等病症和疾病。
Description
本发明涉及具有受体相互作用蛋白激酶1抑制活性的化合物、其制备方法及其用途,特别是该系列化合物或含有该系列化合物的药物组合物以及治疗剂用于治疗与受体相互作用蛋白激酶1相关的炎症性疾病、缺血性疾病、神经退行性疾病、肿瘤等病症和疾病的用途。
蛋白激酶是一种通过对蛋白质上特定氨基酸的磷酸化来调节各种细胞功能的蛋白质(酶)。蛋白质通过构象的改变来调节活性以及与其化组分结合能力。蛋白质激酶的活性指的是,激酶将磷酸基团结合到底物上的速率,该速率可以通过检测一定时间内转化为产物的底物的量来进行测定。底物的磷酸化发生在蛋白质激酶的活化位点上。根据蛋白激酶底物蛋白被磷酸化的氨基酸残基种类,可将蛋白激酶分五类:丝氨酸/苏氨酸蛋白激酶、酪氨酸蛋白激酶、组氨酸蛋白激酶、色氨酸蛋白激酶和天冬氨酰基/谷氨酰基蛋白激酶。其中,丝氨酸/苏氨酸蛋白激酶是一类能够催化多种底物蛋白质上的丝氨酸/苏氨酸残基磷酸化的酶;酪氨酸激酶是一种可以催化将三磷酸腺苷转移到蛋白质酪氨酸残基的蛋白质酶。与蛋白激酶有关的病理状况包括炎症疾病、免疫疾病、心血管疾病和肿瘤等等。
细胞死亡主要包括凋亡、坏死性凋亡、细胞焦亡、铁死亡以及与自噬和非程序性坏死相关的细胞死亡过程。坏死性凋亡,也称为程序性细胞死亡或程序性坏死,是近年研究发现的一种新型细胞死亡方式。程序性坏死是一种高度炎症形式的细胞死亡,程序性坏死导致从细胞释放危险相关分子模式,被认为是多种退行性及炎症疾病的一个重要病理学因素。上述疾病包括神经退行性疾病、中风、冠心病、心肌梗死、视网膜退行性疾病、炎症性肠道病、肾病、肝病,和其他多种相关疾病。受体相互作用蛋白激酶1(RIPK1)与RIPK3是同源的两类丝氨酸/苏氨酸激酶,它们是介导细胞坏死性凋亡的关键元件。
RIPK1激酶被公认是细胞程序性坏死相关疾病的潜在治疗靶标。首创型RIPK1抑制剂Necrostatin-1(Nec-1)及其类似物在临床前研究中,已经对多种退行性疾病、炎症、癌症等疾病展示出明确的疗效。例如,对阿尔茨海默病、帕金森氏症、亨廷顿症、老年性黄斑变性等具有缓解作用;对银屑病、色素性视网膜炎、炎症性肠病、自身免疫性疾病、蛙皮素诱导的急性胰腺炎和败血症/全身炎症反应综合症具有保护作用;能有效缓解缺血性脑损伤、缺血性心肌损伤、视网膜缺血/再灌注损伤、视网膜脱离诱导的感光细胞坏死、青光眼、肾缺血再灌注损伤、顺铂诱导的肾损伤和创伤性脑损伤:至少部分缓解由RIPK1依赖性细胞凋亡、坏死或细胞因子生成所相关的其他疾病,包括血液和实体器官恶性肿瘤、细菌感染和病毒感染(包括结核病、流感等)和溶酶体贮积症(尤其是戈谢病)。另一类RIPK1抑制剂GSK2982772也正处于治疗多种自身免疫性疾病的临床试验当中。
对于用作药剂的激酶抑制剂,尤其是RIPK1激酶抑制剂,存在着需求。然而,现有的靶向程序性坏死相关激酶的抑制剂均存在着不同程度的缺陷,如选择性差、活体抑制活性 仍不够理想、药代性质不佳、口服生物利用度低等,还有一些无法透过血脑屏障进入中枢神经***,这些缺点均限制了其进一步的研究与临床应用。本领域中仍然需要更多化学结构更新颖、理化性质更佳、药效、药代性质更突出的新型激酶抑制剂,以作为检测、预防和治疗涉及坏死性凋亡相关激酶(例如RIPK1)的疾病的候选药物。
发明内容
本发明的目的在于提供RIPK1激酶抑制剂。
本发明的第一方面,提供一种通式(I)所示的化合物或其立体异构体、对映异构体、非对映异构体、阻转异构体、光学异构体、外消旋体、互变异构体或其药学上可接受的盐、其前药、其水合物或溶剂合物、其经同位素标记之化合物,
其中,Cy
1选自下组:
R
5在每次出现时独立地选自:H、D、卤素、CD
3、C1-C8烷基、卤代C1-C8烷基、C1-C8烷氧基、卤代C1-C8烷氧基、氰基、氨基、C1-C8烷基取代的氨基、羟基、巯基、C1-C8烷基硫基;
Cy
2选自被0-5个R
8取代的以下基团:C3-C14环烷基、C6-C14元芳基、6-14元杂芳基、或3-14元杂环基;
R
4在每次出现时独立地选自:H、D、CH
3、CD
3;
各虚线独立地表示单键或双键;
Z
1选自:O、S、N、CR
z1、C=O、SO、SO
2、NH;
Z
2选自C(R
z2)
2、N、CR
z2;各R
z2独立地为H、卤素、羟基、任选取代的C1-C8烷基,或者两个R
z2与它们所连接的碳原子一起形成任选取代的C3-C6碳环或3-6元杂环,
或者R
z2、R
z1与它们所连接的碳原子一起形成任选取代的C3-C6碳环或3-6元杂环;
Z
3、Z
4选自C、CH、N;
环A为C6-C14元芳环、5元杂芳环、6-14元杂芳环、C3-C14碳环或3-14元杂环;
m选自1、2、3、4;
R
1在每次出现时独立地选自H、D、“R
7-C≡C-”、R
1a;较佳地环A上至少有一个R
1为“R
7-C≡C-”的取代基;
R
1a、R
7在每次出现时独立地为由0-5个R
1a2取代的R
1a1;
R
1a1、R
1a2可选被0-5个R
1a3取代;
R
1a3为“-Linker2-R
1a4”;Linker2不存在,或者Linker2选自:键、O、NH、NR
1a4、-C(=O)O-、-C(=O)NH-、-C(=O)NR
1a4-、3-14元环烷基、3-14元杂环基、C6-C14芳基、5-14元杂芳基;
R
2不存在,或者R
2在Z
4的邻位,且与R
3及它们所连接的原子一起形成任选取代或未取代的的5-6元杂环;
R
3选自:H、D、CH
3、CD
3;
Y为O、S、NR
y,其中R
y和R
3与它们所连接的原子一起形成任选取代的5-6元杂环或5-6元杂芳环;
R
6选自:CD
3、C1-C8烷基、卤代C1-C8烷基、C6-C14芳基;
R
8在每次出现时独立地选自:H、D、卤素、CD
3、C1-C8烷基、卤代C1-C8烷基、C1-C8烷氧基、卤代C1-C8烷氧基、氰基、氨基、C1-C8烷基取代的氨基、羟基、巯基、C1-C8烷基硫基、卤代C1-C8烷基硫基、-C(=O)NH2、-C(=O)NH(C1-C8烷基)、-C(=O)-(C1-C8烷基)、氧代、硫代;
R
1a1、R
1a2在每次出现独立地选自下组:H、D、卤素、C1-C8烷基、卤代C1-C8烷基、C1-C8烷氧基、卤代的C1-C8烷氧基、C1-C6烷氧基取代的C1-C6烷氧基、C2-C8烯基、卤代C2-C8烯基、C2-C8烯基氧基、卤代C2-C8烯基氧基、C2-C8炔基、卤代C2-C8炔基、C2-C8炔基氧基、卤代C2-C8炔基氧基、C3-C14环烷基、(C3-C14环烷基)-(C1-C8烷基)-、(C3-C14环烷基)氧基、(C3-C14环烷基)-(C1-C8烷基)氧基、(C3-C14环烷基)氧基(C1-C8烷基)-、(C3-C14环烷基)硫基、(C3-C14环烷基)-(C1-C8烷基)硫基、(C3-C14环烷基)硫基(C1-C8烷基)-、(C3-C14环烷基)NH-、(C3-C14环烷基)-(C1-C8烷基)-NH-、(C3-C14环烷基)-NH-(C1-C8烷基)-、(C3-C14环烷基)-C(=O)-、(C3-C14环烷基)-(C1-C8烷基)-C(=O)-、(C3-C14环烷基)C(=O)-(C1-C8烷基)-、(C3-C14环烷基)-C(=O)O-、(C3-C14环烷基)-(C1-C8烷基)-C(=O)O-、(C3-C14环烷基)-C(=O)O-(C1-C8烷基)-、(C3-C14环烷基)-OC(=O)-、(C3-C14环烷基)-(C1-C8烷基)-OC(=O)-、(C3-C14环烷基)-OC(=O)-(C1-C8烷基)-、(C3-C14环烷基)-C(=O)NH-、(C3-C14环烷基)-(C1-C8烷基)-C(=O)NH-、(C3-C14环烷基)-C(=O)NH-(C1-C8烷基)-、(C3-C14环烷基)-NHC(=O)-、(C3-C14环烷基)-(C1-C8烷基)-NHC(=O)-、(C3-C14环烷 基)-(C1-C8烷基)-NHC(=O)-、(C1-C8烷基)-(C3-C14环烷基)-、羟基(C3-C14环烷基)-、(C1-C8烷氧基)-(C3-C14环烷基)-、羟基(C1-C8烷基)-(C3-C14环烷基)-、巯基(C3-C14环烷基)、(C1-C8烷硫基)-(C3-C14环烷基)-、巯基(C1-C8烷基)-(C3-C14环烷基)-、氨基(C3-C14环烷基)、(C1-C8烷基)NH-(C3-C14环烷基)-、氨基(C1-C8烷基)-(C3-C14环烷基)-、HC(=O)-(C3-C14环烷基)-、(C1-C8烷基)-C(=O)-(C3-C14环烷基)-、HC(=O)-(C1-C8烷基)-(C3-C14环烷基)-、HC(=O)O-(C3-C14环烷基)-、(C1-C8烷基)-C(=O)O-(C3-C14环烷基)-、HC(=O)O-(C1-C8烷基)-(C3-C14环烷基)-、HOC(=O)-(C3-C14环烷基)-、(C1-C8烷基)-O-C(=O)-(C3-C14环烷基)-、HO-C(=O)-(C1-C8烷基)-(C3-C14环烷基)-、HC(=O)NH-(C3-C14环烷基)-、(C1-C8烷基)C(=O)NH-(C3-C14环烷基)-、HC(=O)NH-(C1-C8烷基)-(C3-C14环烷基)-、NH
2C(=O)-(C3-C14环烷基)-、(C1-C8烷基)NHC(=O)-(C3-C14环烷基)-、NH
2C(=O)-(C1-C8烷基)-(C3-C14环烷基)-、(C1-C8烷基)-(C3-C14环烷基)-(C1-C8烷基)-、3-14元杂环基、(3-14元杂环基)-(C1-C8烷基)-、(3-14元杂环基)氧基、(3-14元杂环基)-(C1-C8烷基)-氧基、(3-14元杂环基)氧基-(C1-C8烷基)-、(3-14元杂环基)硫基、(3-14元杂环基)-(C1-C8烷基)-硫基、(3-14元杂环基)硫基-(C1-C8烷基)-、(3-14元杂环基)NH-、(3-14元杂环基)(C1-C8烷基)NH-、(3-14元杂环基)-NH-(C1-C8烷基)-、(3-14元杂环基)-C(=O)-、(3-14元杂环基)-(C1-C8烷基)-C(=O)-、(3-14元杂环基)-C(=O)-(C1-C8烷基)-、(3-14元杂环基)-C(=O)O-、(3-14元杂环基)-(C1-C8烷基)-C(=O)O-、(3-14元杂环基)-C(=O)O-(C1-C8烷基)-、(3-14元杂环基)-OC(=O)-、(3-14元杂环基)-(C1-C8烷基)-OC(=O)-、(3-14元杂环基)-OC(=O)-(C1-C8烷基)-、(3-14元杂环基)-C(=O)NH-、(3-14元杂环基)-(C1-C8烷基)-C(=O)NH-、(3-14元杂环基)-C(=O)NH-(C1-C8烷基)-、(3-14元杂环基)-NHC(=O)-、(3-14元杂环基)-(C1-C8烷基)-NHC(=O)-、(3-14元杂环基)-NHC(=O)-(C1-C8烷基)-、(C1-C8烷基)-(3-14元杂环基)-、羟基(3-14元杂环基)-、(C1-C8烷氧基)-(3-14元杂环基)-、羟基(C1-C8烷基)-(3-14元杂环基)-、巯基(C3-C14环烷基)、(C1-C8烷硫基)-(3-14元杂环基)-、巯基(C1-C8烷基)-(3-14元杂环基)-、氨基(3-14元杂环基)、(C1-C8烷基)NH-(3-14元杂环基)-、氨基(C1-C8烷基)-(3-14元杂环基)-、HC(=O)-(3-14元杂环基)-、(C1-C8烷基)-C(=O)-(3-14元杂环基)-、HC(=O)-(C1-C8烷基)-(3-14元杂环基)-、HC(=O)O-(3-14元杂环基)-、(C1-C8烷基)-C(=O)O-(3-14元杂环基)-、HC(=O)O-(C1-C8烷基)-(3-14元杂环基)-、HOC(=O)-(3-14元杂环基)-、(C1-C8烷基)-O-C(=O)-(3-14元杂环基)-、HO-C(=O)-(C1-C8烷基)-(3-14元杂环基)-、HC(=O)NH-(3-14元杂环基)-、(C1-C8烷基)C(=O)NH-(3-14元杂环基)-、HC(=O)NH-(C1-C8烷基)-(3-14元杂环基)-、NH
2C(=O)-(3-14元杂环基)-、(C1-C8烷基)NHC(=O)-(3-14元杂环基)-、NH
2C(=O)-(C1-C8烷基)-(3-14元杂环基)-、(C1-C8烷基)-(3-14元杂环基)-(C1-C8烷基)-、C6-C14芳基、(C6-C14芳基)-(C1-C8烷基)-、(C6-C14芳基)氧基、(C6-C14芳基)-(C1-C8烷基)氧基、(C6-C14芳基)氧基(C1-C8烷基)-、(C6-C14芳基)硫基、(C6-C14芳基)-(C1-C8烷基)硫基、(C6-C14芳基)硫基(C1-C8烷基)-、(C6-C14芳基)NH-、(C6-C14芳基)-(C1-C8烷基)-NH-、(C6-C14芳基)-NH-(C1-C8烷基)-、(C6-C14芳基)-C(=O)-、(C6-C14芳基)-(C1-C8烷基)-C(=O)-、(C6-C14芳基)C(=O)-(C1-C8烷基)-、(C6-C14芳基)-C(=O)O-、(C6-C14芳基)-(C1-C8烷基)-C(=O)O-、(C6-C14芳基)-C(=O)O-(C1-C8烷基)-、(C6-C14芳基)-OC(=O)-、(C6-C14芳 基)-(C1-C8烷基)-OC(=O)-、(C6-C14芳基)-OC(=O)-(C1-C8烷基)-、(C6-C14芳基)-C(=O)NH-、(C6-C14芳基)-(C1-C8烷基)-C(=O)NH-、(C6-C14芳基)-C(=O)NH-(C1-C8烷基)-、(C6-C14芳基)-NHC(=O)-、(C6-C14芳基)-(C1-C8烷基)-NHC(=O)-、(C6-C14芳基)-(C1-C8烷基)-NHC(=O)-、(C1-C8烷基)-(C6-C14芳基)-、羟基(C6-C14芳基)-、(C1-C8烷氧基)-(C6-C14芳基)-、羟基(C1-C8烷基)-(C6-C14芳基)-、巯基(C3-C14环烷基)、(C1-C8烷硫基)-(C6-C14芳基)-、巯基(C1-C8烷基)-(C6-C14芳基)-、氨基(C6-C14芳基)、(C1-C8烷基)NH-(C6-C14芳基)-、氨基(C1-C8烷基)-(C6-C14芳基)-、HC(=O)-(C6-C14芳基)-、(C1-C8烷基)-C(=O)-(C6-C14芳基)-、HC(=O)-(C1-C8烷基)-(C6-C14芳基)-、HC(=O)O-(C6-C14芳基)-、(C1-C8烷基)-C(=O)O-(C6-C14芳基)-、HC(=O)O-(C1-C8烷基)-(C6-C14芳基)-、HOC(=O)-(C6-C14芳基)-、(C1-C8烷基)-O-C(=O)-(C6-C14芳基)-、HO-C(=O)-(C1-C8烷基)-(C6-C14芳基)-、HC(=O)NH-(C6-C14芳基)-、(C1-C8烷基)C(=O)NH-(C6-C14芳基)-、HC(=O)NH-(C1-C8烷基)-(C6-C14芳基)-、NH
2C(=O)-(C6-C14芳基)-、(C1-C8烷基)NHC(=O)-(C6-C14芳基)-、NH
2C(=O)-(C1-C8烷基)-(C6-C14芳基)-、(C1-C8烷基)-(C6-C14芳基)-(C1-C8烷基)-、5-14元杂芳基、(5-14元杂芳基)-(C1-C8烷基)-、(5-14元杂芳基)氧基、(5-14元杂芳基)-(C1-C8烷基)氧基、(5-14元杂芳基)氧基(C1-C8烷基)-、(5-14元杂芳基)硫基、(5-14元杂芳基)-(C1-C8烷基)硫基、(5-14元杂芳基)硫基(C1-C8烷基)-、(5-14元杂芳基)NH-、(5-14元杂芳基)-(C1-C8烷基)-NH-、(5-14元杂芳基)-NH-(C1-C8烷基)-、(5-14元杂芳基)-C(=O)-、(5-14元杂芳基)-(C1-C8烷基)-C(=O)-、(5-14元杂芳基)C(=O)-(C1-C8烷基)-、(5-14元杂芳基)-C(=O)O-、(5-14元杂芳基)-(C1-C8烷基)-C(=O)O-、(5-14元杂芳基)-C(=O)O-(C1-C8烷基)-、(5-14元杂芳基)-OC(=O)-、(5-14元杂芳基)-(C1-C8烷基)-OC(=O)-、(5-14元杂芳基)-OC(=O)-(C1-C8烷基)-、(5-14元杂芳基)-C(=O)NH-、(5-14元杂芳基)-(C1-C8烷基)-C(=O)NH-、(5-14元杂芳基)-C(=O)NH-(C1-C8烷基)-、(5-14元杂芳基)-NHC(=O)-、(5-14元杂芳基)-(C1-C8烷基)-NHC(=O)-、(5-14元杂芳基)-(C1-C8烷基)-NHC(=O)-、(C1-C8烷基)-(5-14元杂芳基)-、羟基(5-14元杂芳基)-、(C1-C8烷氧基)-(5-14元杂芳基)-、羟基(C1-C8烷基)-(5-14元杂芳基)-、巯基(C3-C14环烷基)、(C1-C8烷硫基)-(5-14元杂芳基)-、巯基(C1-C8烷基)-(5-14元杂芳基)-、氨基(5-14元杂芳基)、(C1-C8烷基)NH-(5-14元杂芳基)-、氨基(C1-C8烷基)-(5-14元杂芳基)-、HC(=O)-(5-14元杂芳基)-、(C1-C8烷基)-C(=O)-(5-14元杂芳基)-、HC(=O)-(C1-C8烷基)-(5-14元杂芳基)-、HC(=O)O-(5-14元杂芳基)-、(C1-C8烷基)-C(=O)O-(5-14元杂芳基)-、HC(=O)O-(C1-C8烷基)-(5-14元杂芳基)-、HOC(=O)-(5-14元杂芳基)-、(C1-C8烷基)-O-C(=O)-(5-14元杂芳基)-、HO-C(=O)-(C1-C8烷基)-(5-14元杂芳基)-、HC(=O)NH-(5-14元杂芳基)-、(C1-C8烷基)C(=O)NH-(5-14元杂芳基)-、HC(=O)NH-(C1-C8烷基)-(5-14元杂芳基)-、NH
2C(=O)-(5-14元杂芳基)-、(C1-C8烷基)NHC(=O)-(5-14元杂芳基)-、NH
2C(=O)-(C1-C8烷基)-(5-14元杂芳基)-、(C1-C8烷基)-(5-14元杂芳基)-(C1-C8烷基)-、羟基、羟基取代的C1-C8烷基、巯基、巯基取代的C1-C8烷基、氨基、氨基取代的C1-C8烷基、-NH(C1-C8烷基)、-N(C1-C8烷基)(C1-C8烷基)、氰基、氰基取代的C1-C8烷基、-COOH、-(C1-C8烷基)-COOH、-C(=O)O-(C1-C8烷基)、-(C1-C8烷基)-C(=O)O-(C1-C8烷基)、-OC(=O)H、-(C1-C8烷基)-OC(=O)H、-OC(=O)-(C1-C8烷基)、-(C1-C8烷基)-OC(=O)-(C1-C8 烷基)、-C(O)H、-(C1-C8烷基)-C(=O)H、-C(=O)-(C1-C8烷基)、-(C1-C8烷基)-C(=O)-(C1-C8烷基)、NH
2C(=O)-、一个或二个C1-C8烷基取代的NH
2C(O)-、一个或二个C1-C8环烷基取代的NH
2C(O)-、一个或二个C6-C14芳基取代的NH
2C(O)-、一个或二个5-14元杂芳基取代的NH
2C(O)-、一个或二个4-10元杂环基取代的NH
2C(O)-、NH
2C(=O)-(C1-C8烷基)-、一个或二个C1-C8烷基取代的NH
2C(O)-(C1-C8烷基)-、一个或二个C1-C8环烷基取代的NH
2C(O)-(C1-C8烷基)-、一个或二个C6-C14芳基取代的NH
2C(O)-(C1-C8烷基)-、一个或二个5-14元杂芳基取代的NH
2C(O)-(C1-C8烷基)-、一个或二个4-10元杂环基取代的NH
2C(O)-(C1-C8烷基)-、氧代(=O)、硫代(=S);
R
1a4在每次出现时独立地选自下组:H、D、卤素、羟基、C1-C8烷基、卤代C1-C8烷基、C2-C8烯基、卤代C2-C8烯基、C2-C8炔基、卤代C2-C8炔基、(C1-C15烷基)-OC(=O)-、(C6-C14芳基)-OC(=O)-、(4-12元杂环基)-OC(=O)-、(5-14元杂芳基)-OC(=O)-、(C1-C15烷基)-C(=O)-、(C6-C14芳基)-C(=O)-、(4-12元杂环基)-C(=O)-、(5-14元杂芳基)-C(=O)-、(C1-C15烷基)-C(=O)O-、(C6-C14芳基)-C(=O)O-、(4-12元杂环基)-C(=O)O-、(5-14元杂芳基)-C(=O)O-、(卤代C1-C15烷基)-OC(=O)-、(卤代C6-C14芳基)-OC(=O)-、(卤代4-12元杂环基)-OC(=O)-、(卤代5-14元杂芳基)-OC(=O)-、(卤代C1-C15烷基)-C(=O)-、(卤代C6-C14芳基)-C(=O)-、(卤代4-12元杂环基)-C(=O)-、(卤代5-14元杂芳基)-C(=O)-、(卤代C1-C15烷基)-C(=O)O-、(卤代C6-C14芳基)-C(=O)O-、(卤代4-12元杂环基)-C(=O)O-、(卤代5-14元杂芳基)-C(=O)O-、C1-C8烷基取代的(C1-C15烷基)-OC(=O)-、C1-C8烷基取代的(C6-C14芳基)-OC(=O)-、C1-C8烷基取代的(4-12元杂环基)-OC(=O)-、C1-C8烷基取代的(5-14元杂芳基)-OC(=O)-、C1-C8烷基取代的(C1-C15烷基)-C(=O)-、C1-C8烷基取代的(C6-C14芳基)-C(=O)-、C1-C8烷基取代的(4-12元杂环基)-C(=O)-、C1-C8烷基取代的(5-14元杂芳基)-C(=O)-、C1-C8烷基取代的(C1-C15烷基)-C(=O)O-、C1-C8烷基取代的(C6-C14芳基)-C(=O)O-、C1-C8烷基取代的(4-12元杂环基)-C(=O)O-、C1-C8烷基取代的(5-14元杂芳基)-C(=O)O-、(C1-C8烷基)
3-Si-(C1-C8烷基)-O-(C1-C8亚烷基)-、被卤素取代或未取代的(C1-C8烷基)-OC(=O)-(C1-C8烷基)C(=O)O-、被卤素取代或未取代的(C1-C8烷基)-OC(=O)-(C3-C14环烷基)C(=O)O-、糖基、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(NH-(C1-C8烷基)C(=O)O(C1-C8烷基))、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(O-(C1-C8烷基)C(=O)O(C1-C8烷基))、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(NH-(C1-C8烷基)OC(=O)(C1-C8烷基))、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(O-(C1-C8烷基)OC(=O)(C1-C8烷基))、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(NH-(C1-C8烷基)-S-C(=O)(C1-C8烷基))、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(O-(C1-C8烷基)-S-C(=O)(C1-C8烷基))、-O-P(=O)(ONa)
2、-O-P(=O)(OK)
2、-O-P(=O)(OLi)
2、-O-(卤代或未卤代的C1-C8烷基)-P(=O)(O-C1-C8烷基)
2、(C1-C8烷基)-C(=O)-CH=CH-、氨基酸酰基、C1-C16烷基、卤代C1-C16烷基、C6-C14芳基、卤代C6-C14芳基。
在另一优选例中,至少一个R
1为R
7-C≡C-”。即m为1,R
1为R
7-C≡C-”;m为2、3或4,其中一个R
1为R
7-C≡C-”,其他R
1独立地选自H、D、“R
7-C≡C-”、R
1a。
在另一优选例中,通式(I)所示的化合物具有结构:
在另一优选例中,通式(I)所示的化合物具有式(II)所示的结构:
在另一优选例中,所述化合物选自式(IV-1)、(IV-2)、(IV-4)、(IV-5)、(IV-6)、(IV-7)、(IV-9):
其中,Cy
3选自式(III-1)至(III-14):
Z
5选自C-R
1或N;R
1、m、Z
1、R
3的定义同前;较佳地,Z
5选自CH或N;m为1时,R
1为R
7-C≡C-;R
7的定义同前。
在另一优选例中,所述化合物选自式(V-1)、(V-2)、(V-3)、(V-4):
其中,Z
5选自C-R
1或N;R
1a1、R
1、R
3、Z
1、Cy
1、Cy
2、R
5的定义同前。
在另一优选例中,所述化合物选自:
式中,Z
5选自CH或N;R
1为C1-C8烷基;R
1a1、R
3、Z
1、Cy
2、R
5的定义同前。
在另一优选例中,所述化合物为权利要求5中列出的化合物。
本发明的第二方面,提供第一方面所述式(I)所示化合物的制备方法,合成步骤至少包括反应式1、反应式2之一所述反应式:
[反应式1]
[反应式2]
其中,
G
2选自:-OH,卤素,C1-C8烷氧基,C6-C14芳基氧基,-OC(=O)-(C1-C8烷氧基),-OS(=O)-(C1-C8烷氧基),-OS(=O)
2-(C1-C8烷氧基),-OC(=O)-(C6-C14芳基氧基),-OS(=O)-(C6-C14芳基氧基),-OS(=O)
2-(C6-C14芳基氧基);
R
4、R
1、m、R
2、R
3、Y、Z
1、Z
2、Z
3、Z
4、虚线、Cy
1的定义同前。
本发明的第三方面,提供药物组合物,包含:药学上可接受的载体和一种或多种第一方面所述的化合物或其立体异构体、对映异构体、非对映异构体、阻转异构体、光学异构体、外消旋体、互变异构体或其药学上可接受的盐、其前药、其水合物或溶剂合物、其经同位素标记之化合物。
本发明的第四方面,提供一种受体相互作用蛋白激酶1(RIPK1)抑制剂,包含一种或多种第一方面所述的化合物或其立体异构体、几何异构体、互变异构体、其药学上可接受的盐、其前药、其水合物或溶剂合物,或第三方面所述的药物组合物。
本发明的第五方面,提供第一方面所述化合物或其立体异构体、对映异构体、非对映异构体、阻转异构体、光学异构体、外消旋体、互变异构体或其药学上可接受的盐、其前药、其水合物或溶剂合物、其经同位素标记之化合物或第三方面所述的药物组合物的用途,其特征在于,用于制备药物,所述药物用于:1)检测和/或预防和/或治疗激酶相关疾病;2)检测和/或预防和/或治疗免疫、炎症和/或感染相关疾病;3)检测和/或预防和/或治疗缺血和/或再灌注损伤相关疾病;4)检测和/或预防和/或治疗退行性疾病;5)检测和/或预防和/或***相关疾病;6)检测和/或预防和/或治疗细胞坏死相关疾病;7)检测和/或预防和/或治疗代谢相关疾病;或者8)检测和/或预防和/或治疗眼部疾病。
本发明的第六方面,提供第一方面所述化合物或其立体异构体、对映异构体、非对映异构体、阻转异构体、光学异构体、外消旋体、互变异构体或其药学上可接受的盐、其前药、其水合物或溶剂合物、其经同位素标记之化合物或第三方面所述的药物组合物的用途,其特征在于,用于制备检测和/或预防和/或治疗选自下组的疾病的药物:
全身型幼年特发性关节炎,***,白细胞介素‐1转化酶相关性发热综合征,败血症,斑秃,变应性疾病,过敏性疾病,乙型肝炎,丙型肝炎,多发性硬化,肺结节病,肺纤维化,肺炎,分枝杆菌感染,腹腔疾病,干燥综合征,骨关节炎,化脓性汗腺炎,坏死性小肠结肠炎,急性胰腺炎,脊柱关节炎,结肠炎,局限性回肠炎,抗磷脂综合征,克罗恩病,溃疡性肠炎,类风湿性关节炎,细菌感染,流感,慢性阻塞性肺病,病毒感染,脓毒症,皮炎,葡萄球菌感染,自身免疫疾病,全身性红斑狼疮,全身性炎症反应综合征,全身性硬皮病,朊病毒症,肾上腺皮质变性,肾炎,史‐约综合征,手术感染,特应性皮炎,韦格纳肉芽肿,***性红斑狼疮,哮喘,新冠肺炎,血管炎,牙周炎,炎性肠病,胰腺炎,移植器官排除,银屑病,原发性硬化性胆管炎,肿瘤坏死因子受体相关周期性发热综合征,白细胞介素‐1转换酶相关的发热综合征,自身免疫特发性血小板减少性紫癜,Fahr病,GM1神经节苷脂贮积病,GM2神经节苷脂贮积病,艾滋病相关痴呆综合征,Tau蛋白病,阿尔茨海默病,帕金森病,路易体痴呆,多***萎缩症,多重硬化,额颞叶痴呆,法伯病,弗里德赖希共济失调症,格林巴利综合征,亨廷顿病,原发性侧索硬化,肌萎缩性侧索硬化,脊髓性肌萎缩,假性延髓麻痹,进行性延髓麻痹,结节状硬化症,进行性核上性麻痹,进行性肌萎缩,精神***症,脱髓鞘病,慢性炎症性脱髓鞘性多发性神经病,尼曼匹克病,皮质基底节变性,溶酶体贮积病,桑德霍夫病,神经节细胞病,神经元蜡样脂褐质沉积症,术后认知障碍,双相障碍,糖尿病性神经病,疼痛(神经疼痛),谵妄,抑郁症,周围神经病变,自闭症,创伤,创伤性脑损伤,局部缺血,创伤性视网膜损伤,脑血管意外,脑卒中,地理性萎缩,对乙酰胺基酚中毒,急性肝衰竭,急性肾损伤,急性呼吸窘迫综合征,颅内出血,脑出血,脑缺血,缺血,缺血性损伤,缺氧性脑损伤,缺氧,烧伤,烧伤性休克,实体器官的缺血再灌注损伤,顺铂诱导的肾损伤,吸烟诱导的损伤,心肌梗塞,心力衰竭,中毒性表皮坏死松解症,急性肾小管坏死,心脏衰竭,NF‐κB关键调节基因突变,白血病,髓细胞白血病,淋巴细胞白血病,T细胞白血病,淋巴瘤,T细胞淋巴瘤,鼻咽癌,表皮样癌,垂体腺瘤,胆道癌肉瘤,胆管癌,多发性骨髓瘤,儿童实体瘤,霍奇金病,非霍奇金淋巴瘤,非小细胞肺癌,小细胞肺癌,***区域癌,睾丸癌,***,子宫癌,子宫内膜癌,卵巢癌,骨癌,骨肉瘤,黑色素瘤,环境诱发的癌症,脊柱肿瘤,甲状腺癌,甲状旁腺癌,胶质母细胞瘤,结肠直肠癌,卡波西氏肉瘤,鳞状上皮细胞癌,脑胶质瘤,内分泌***癌症,尿道癌,膀胱癌,皮肤癌,皮肤或眼内恶性黑色素瘤,***癌,三阴性乳腺癌,神经胶质瘤,肾或输尿管癌,肾盂癌,肾上腺癌,实体器官恶性肿瘤,食道癌,输卵管癌,头和/或颈癌,外阴癌,胃癌,胃肠间质瘤,小肠癌,血液恶性肿瘤,胰腺癌,遗传性大动脉瘤,***癌,***癌,直肠癌,肿瘤血管生成,黄斑病变,黄斑裂孔,黄斑毛细管扩张,干眼症,进行性视网膜萎缩,莱伯氏先天性黑蒙,囊性黄斑水肿,年龄相关性黄斑变性,青光眼,视网膜神经变性,缺血性视神经病变,缺血性视网膜疾病,糖尿病性视网膜病变,色素性视网膜炎,视网膜感光器疾病,视网膜退行性疾病,视神经疾病,视网膜脱离,医源性视网膜损伤,视网膜血管疾病,视锥视杆营养不良,无脉络膜症,眼底疾病,眼血管疾病,尤塞氏综合症,I型糖尿病,非酒精性脂肪肝,白癜风,唾液酸苷贮积症,肠易激综合征,达农病,胆固醇酯贮积症,沃尔曼病, 低脂血症,动脉粥样硬化,多种硫酸酯酶缺乏症,法布里病,戈谢病,骨髓纤维化,骨质疏松症,胱氨酸贮积症,肌营养不良,多聚谷氨酰胺疾病,克拉伯病,慢性肾病,门克斯病,囊性纤维化病,庞皮病,泰伊‐萨克斯二氏病,溶酶体酸脂酶缺乏,天冬氨酰葡萄糖胺尿症,痛风,威尔逊氏病,线粒体病症,岩藻糖苷贮积症,异染性脑白质营养不良,浴酶体酸脂酶缺乏,粘多糖累积病,粘脂质累积,致密性成骨不全症,血色病,Niemann‐Pick病,Heme‐氧化的IRP2泛素连接酶‐1缺乏,骨坏死,链状泛素链组装复合物缺乏综合征,纤毛病等。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。说明书中所揭示的各个特征,可以被任何提供相同、均等或相似目的的替代性特征取代。限于篇幅,在此不再一一累述。
具体实施方法
本发明人经过长期而深入的研究,意外地研发出一种结构新颖、激酶抑制作用显著的通式(I)和/或通式(II)所示化合物。所述的激酶抑制剂具有优异的RIPK1抑制活性,因此可用于制备检测和/或预防和/或治疗涉及细胞死亡和/或相关的疾病的药物组合物。在此基础上,发明人完成了本发明。
术语
除非明确另外指出,根据本发明和本文所用的术语具有以下含义:
术语“C
1-C
6”是指具有1、2、3、4、5或6个碳原子,“C
1-C
8”是指具有1、2、3、4、5、6、7或8个碳原子,依此类推。“5-8元”是指具有5-8个环原子,依此类推。
“取代基”指可以取代被取代基物中的氢原子的原子或基团。示例如下(但并不限于下列示例):氘代、烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、异氰酸基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氨基、卤代烷基、羟烷基、羧基、羧酸酯基、氧代、硫代、-C(=O)R
n、-C(=O)OR
n、-C(=O)NR
nR
o、-NR
nR
o、-NR
nC(=O)R
o、-NR
nC(=O)OR
o、NR
nC(=O)NR
oR
p、-NR
nS(=O)R
o、NR
nS(=O)NR
oR
p、-NR
nS(=O)
2R
o、NR
nS(=O)
2NR
oR
p、-OR
n、-SR
n、-OC(=O)R
n、-OC(=O)NR
nR
o、-OC(=O)OR
n、-S(=O)NR
nR
o、-S(=O)
2NR
nR
o、-BR
nR
o、B(OR
n)(OR
o)、-SiR
nR
oR
p、-OP(=O)R
nR
o、-P(=O)R
nR
o、-OP(=O)
2R
n、-P(=O)
2R
n、-NP(=O)R
nR
o、-NP(=O)R
nR
o、-NP(=O)
2R
n、-NP(=O)
2R
n等,其中R
n、R
o、R
p在每次出现时独立地选自下组:H、D、C1-C12烷基、卤代的C1-C12烷基、C1-C12杂烷基、卤代的C1-C12杂烷基、C3-C12环烷基、卤代的C3-C12环烷基、C3-C12芳基、卤代的C3-C12芳基、C3-C12芳基、卤代的C3-C12芳基、C3-C12杂芳基、卤代的C3-C12杂芳基;可选的,R
n、R
o及它们所连的原子一起可以形成环结构。本领域技术人员应理解,本发明所预期的取代基与被取代物的组合是那些稳定的或化学上可实现的组合。
“取代”指特定的基团上的一个或多个氢原子被特定的取代基所取代。特定的取代基为在前文中相应描述的取代基,或各实施例中所出现的取代基。除非特别说明,某个取代的基团可以在该基团的任何可取代的位点上具有一个选自特定组的取代基,所述的取代基在各个位置上可以是相同或不同的。本领域技术人员应理解,本发明所预期的取代基的组合是那些稳定的或化学上可实现的组合。所述取代基例如(但并不限于):烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、疏基、羟基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氨基、卤代烷基、羟烷基、羧基、羧酸酯基、氧代、硫代、-C(=O)R
n、-C(=O)OR
n、-C(=O)NR
nR
o、-NR
nR
o、-NR
nC(=O)R
o、-NR
nC(=O)OR
o、NR
nC(=O)NR
oR
p、-NR
nS(=O)R
o、NR
nS(=O)NR
oR
p、-NR
nS(=O)
2R
o、NR
nS(=O)
2NR
oR
p、-OR
n、-SR
n、-OC(=O)R
n、-OC(=O)NR
nR
o、-OC(=O)OR
n、-S(=O)NR
nR
o、-S(=O)
2NR
nR
o、-BR
nR
o、B(OR
n)(OR
o)、-SiR
nR
oR
p、-OP(=O)R
nR
o、-P(=O)R
nR
o、-OP(=O)
2R
n、-P(=O)
2R
n、-NP(=O)R
nR
o、-NP(=O)R
nR
o、-NP(=O)
2R
n、-NP(=O)
2R
n等,其中R
n、R
o、R
p的定义同前述。
“烷基”指饱和的脂肪族烃基,可以是直链或支链的。所述烷基可以独立地被一个或多个本发明所描述地取代基所取代。烷基基团更近一步地实例包括但不限于甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、3-甲基戊基。烷基可以是任选取代或未取代的。
“烯基”直链或支链的烃基,其中至少一个C-C为sp
2双键,其中烯基的基团可以独立任选地被一个或多个本发明所描述的取代基所取代,其中具体的实例包括,但并不限于乙烯基、烯丙基、烯丁基、
等等。烯基可以是任选取代或未取代的。
“炔基”指直链或支链的烃基,其中至少一个C-C为sp三键,其中炔基基团可以独立任选地被一个或多个本发明所描述的取代基所取代,具体的实例包括,但并不限于乙炔基、1-丙炔基、2-丙炔基、1-、2-或3-丁炔基等。炔基可以是任选取代或未取代的。
“环结构”指单环或多环结构。通常为环状结构中的某一个原子上相连的两个或多个片段相连进而形成了闭合的结构,包括但不限于环烷烃、杂环烷烃、环内酰胺、芳烃、杂芳烃、并环、桥环、螺环等结构,示例如下(但并不限于下列示例):环丙烷、环丁烷、氧杂环丁烷、环戊烷、环己烷、金刚烷、环己烯、环辛炔、吡唑、苯、吡啶、3,4-二氢-1,4-苯并氧氮杂卓-5(2H)-酮、萘、蒽、菲、喹啉、吡咯并吡啶、吡唑并吡啶、吲哚、二氢吲哚、甾环、卟啉环等。所述环结构可以是任选取代或未取代的。当其作为取代基出现时,指单环或多环上的一个或多个氢原子被移除,从而可以作为被取代物的取代基。
“卤素”指F、Cl、Br或I。
“卤代”指被一个或多个卤素取代。
“芳基”指含有一个或多个环的碳环芳香***,所述环上不含杂原子。可选地,所述芳基可以与杂芳基、杂环基或其它环结构稠合。示例如下(但并不限于下列示例):苯基、 萘基、四氢萘基、
等。所述芳基可以是任选取代的或未取代的。当所述芳基描述形式为“C6-C14芳基”时,指的是所述芳基与母体结构连接在一起的芳环具有6-14个碳原子,但所述芳基可选与其它环结构稠合,所述其它环结构指具有3-18个环原子的环结构,所述其它环结构可以是任选取代或未取代的。
“杂芳基”指含有一个或多个环的芳香族环结构,其可以包含一个或多个选自N、O或S原子。可选地,所述芳基可以与芳基、杂环基、环烷基或其它环结构稠合。示例如下(但并不限于下列示例):呋喃基、噻吩基、吡啶基、吡唑基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、咪唑基、四唑基、
等。所述杂芳基可以是任选取代的或未取代的。当所述杂芳基描述形式为“5-14元杂芳基”时,指的是所述杂芳基与母体结构连接在一起的杂芳环具有5-14个环原子,但所述杂芳基可选与其它环结构稠合,所述其它环结构指具有3-18个环原子环结构,所述其它环结构可以是任选取代或未取代的。
“环烷基”指饱和或部分不饱和单环或多环环状烃取代基。所述环烷基与被取代物直接相连的第一个环结构是非芳香性的。单环环烷基的示例(但并不限于下列示例):环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基、环辛炔基等;多环环烷基的示例(但并不限于下列示例):螺环、稠环和桥环的环烷基。可选地,所述环烷基可以与芳基、杂环基、环烷基或其它环结构稠合或形成螺环。与其它环结构稠合或形成螺环的示例(但并不限于下列示例):
所述环烷基可以是任选取代的或未取代的。当所述环烷基基描述形式为“C3-C14环烷基”时,指的是所述环烷基与母体结构连接在一起的环烷基环具有3-14个碳原子,但所述环烷基可选与其它环结构稠合或形成螺环,所述其它环结构指具有3-18个环原子环结构,所述其它环结构可以是任选取代或未取代的。
“杂环基”指至少一个环原子原子是杂原子(例如O、N、S原子等)的饱和或部分不饱和的单环或多环环状结构。示例如下(但并不限于下列示例):四氢呋喃基、四氢吡喃基、四氢吡咯基、四氢噻吩基、哌啶基、哌嗪基、氮杂环丁基、氮杂环庚基、吗啉基、2-氧代-吡咯烷基、哌嗪-2-酮、8-氧杂-3-氮杂-双环[3.2.1]辛基等。所述杂环基环可以稠合于芳基、杂芳基或环烷基环上,其中与母体结构连接在一起的环为杂环基。所述杂环基可以是任选取代的或未取代的。当所述杂烷基基描述形式为“3-14元杂环基”时,指的是所述杂环基与母体结构连接在一起的杂环基环具有3-14个环原子,但所述杂环基可选与其它环结构稠合或形成螺环,所述其它环结构指具有3-18个环原子环结构,所述其它环结构可以是任选取代或未取代的。
“互变异构体”表示具有不同能量的结构同分异构体可以超过低能垒,从而互相转化。比如,质子互变异构体(即质子移变)包括通过质子迁移进行互变,如1H-吲唑与2H-吲唑、1H-苯并[d]咪唑与3H-苯并[d]咪唑,化合价互变异构体包括通过一些成键电子重组而进行互变。
“立体异构体”表示具有相同连接而不同空间排列方式原子的分子。比如,含有一个手性中心、具有相同二维连接方式的两个化合物,如R-甘油醛与S-甘油醛、R-丝氨酸与S-丝氨酸。
“对映异构体”表示互为实物与镜像关系,且不可重叠的立体异构体。比如R-丝氨酸与S-丝氨酸。
“非对映异构体”表示分子具有两个或多个手性中心,并且分子间为非镜像的关系的立体异构体。比如酒石酸。
“阻转异构体”表示表示分子因为围绕单键的旋转受阻碍而产生的一组构象异构体。比如6,6'-二硝基-2,2'-联苯二甲酸的各个立体异构体。
“光学异构体”表示两个或多个分子具有相同二维连接方式,但由于构型上的差异而表现出不同旋光性能的化合物。比如左旋氨氯地平与右旋氨氯地平。
“外消旋体”表示具有相同二维连接方式但互为光学异构体的化合物,混合在一起最终表现为无旋光性能的物质。比消旋氨氯地平。
术语“氨基酸酰基”指氨基酸的羧基转化为酰基,并通过该酰基连接到被取代物的取代基。示范性实例包换但不限于下述例子:甘氨酸酰基的结构,是把甘氨酸(NH
2-CH
2-COOH)的羧基转化为酰基,获得甘氨酸酰基(NH
2-CH
2-C(=O)-)。所述氨基酸包括但不限于α-氨基酸、β-氨基酸、γ-氨基酸、ω-氨基酸。所述氨基酸包括但不限于下述示例:甘氨酸、 丙氨酸、缬氨酸、亮氨酸、异亮氨酸、甲硫氨酸(蛋氨酸)、脯氨酸、色氨酸、丝氨酸、酪氨酸、半胱氨酸、苯丙氨酸、天冬酰胺、谷氨酰胺、苏氨酸、天门冬氨酸、谷氨酸、赖氨酸、精氨酸、组氨酸、硒半胱氨酸、吡咯赖氨酸、β-丙氨酸等。
术语“糖基”指单糖或低聚糖通过提供半缩醛羟基的形式形成的取代基。所述单糖包括醛糖和酮糖。所述单糖包括丙糖、丁糖、戊糖、己糖、庚糖。所述低聚糖又名寡糖,指含有2-11个单糖,且各单糖通过糖苷键聚合而成的化合物。所述单糖或多糖的示例如下(但并不限于下列示例):赤藓糖、苏力糖、***糖、核糖、木糖、来苏糖、葡萄糖、甘露糖、果糖、半乳糖、乳糖、蔗糖、麦芽糖、α-环糊精、β-环糊精、γ-环糊精。
本发明所述药学上可接受的盐可以是阴离子与式(I)化合物上带正电荷的基团形成的盐。合适的阴离子为氯离子、溴离子、碘离子、硫酸根、硝酸根、磷酸根、柠檬酸根、甲基磺酸根、三氟乙酸根、乙酸根、苹果酸根、甲苯磺酸根、酒石酸根、富马酸根、谷氨酸根、葡糖醛酸根、乳酸根、戊二酸根或马来酸根。类似地,可以由阳离子与式(I)化合物上的带负电荷的基团形成盐。合适的阳离子包括钠离子、钾离子、镁离子、钙离子和铵离子,例如四甲基铵离子。
在另一优选例中,“药学上可接受的盐”是指式(I)化合物同选自下组的酸形成的盐类:氢氟酸、盐酸、氢溴酸、磷酸、乙酸、草酸、硫酸、硝酸、甲磺酸、胺基磺酸、水杨酸、三氟甲磺酸、萘磺酸、马来酸、柠檬酸、醋酸、乳酸、酒石酸、琥珀酸、酢浆草酸、丙酮酸、苹果酸、谷氨酸、对甲苯磺酸、萘磺酸、乙磺酸、萘二磺酸、丙二酸、富马酸、丙酸、草酸、三氟乙酸、硬酯酸、扑酸、羟基马来酸、苯乙酸、苯甲酸、谷氨酸、抗坏血酸、对胺基苯磺酸、2-乙酰氧基苯甲酸和羟乙磺酸等;或者式(I)化合物与无机碱形成的钠盐、钾盐、钙盐、铝盐或铵盐;或者通式I化合物与有机碱形成的甲胺盐、乙胺盐或乙醇胺盐。
药物组合物
本发明提供了一种药物组合物,包含药学上可接受的载体和一种或多种治疗有效量的本发明的化合物或其立体异构体、对映异构体、非对映异构体、阻转异构体、光学异构体、外消旋体、互变异构体或其药学上可接受的盐、其前药、其水合物或溶剂合物、其经同位素标记之化合物。
本发明的药物组合物包含安全有效量范围内的本发明化合物或其药理上可接受的盐及药理上可以接受的赋形剂或载体。其中“安全有效量”指的是:化合物的量足以明显改善病情,而不至于产生严重的副作用。通常,药物组合物含有1-2000mg本发明化合物/剂,更佳地,含有50-200mg本发明化合物/剂。较佳地,所述的“一剂”为一个胶囊或药片。
“药学上可以接受的载体”指的是:一种或多种相容性固体或液体填料或凝胶物质,它们适合于人使用,而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明的化合物以及它们之间相互掺和,而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化 剂(如
)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
所述的药物组合物为注射剂、囊剂、片剂、丸剂、散剂或颗粒剂。
本发明化合物或药物组合物的施用方式没有特别限制,代表性的施用方式包括(但并不限于):口服、瘤内、直肠、肠胃外(静脉内、肌肉内或皮下)、和局部给药。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中,活性化合物与至少一种常规惰性赋形剂(或载体)混合,如柠檬酸钠或磷酸二钙,或与下述成分混合:(a)填料或增容剂,例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;(b)粘合剂,例如,羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和***胶;(c)保湿剂,例如,甘油;(d)崩解剂,例如,琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠;(e)缓溶剂,例如石蜡;(f)吸收加速剂,例如,季胺化合物;(g)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯;(h)吸附剂,例如,高岭土;和(i)润滑剂,例如,滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠,或其混合物。胶囊剂、片剂和丸剂中,剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备,如肠衣和其它本领域公知的材料。它们可包含不透明剂,并且,这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时,活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外,液体剂型可包含本领域中常规采用的惰性稀释剂,如水或其它溶剂,增溶剂和乳化剂,例知,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油,特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外,组合物也可包含助剂,如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外,悬浮液可包含悬浮剂,例如,乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液,和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂,或必要时可能需要的推进剂一起混合。
本发明化合物可以单独给药,或者与其他药学上可接受的其他化合物(如抗肿瘤药物)联合给药。
本发明治疗方法可以单独施用,或者与其它治疗手段或者治疗药物联用。
使用药物组合物时,是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人),其中施用时剂量为药学上认为的有效给药剂量,对于60kg体重的人而言,日给药剂量通常为1~2000mg,优选5~500mg。当然,具体剂量还应考虑给药途径、病人健康状况等因素,这些都是熟练医师技能范围之内的。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件(如Sambrook等人,分子克隆:实验室手册(New York:Cold Spring Harbor Laboratory Press,1989)中所述的条件)或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数是重量百分比和重量份数。
除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
缩写定义
HATU:N,N,N′,N′-四甲基-O-(7-氮杂苯并***-1-基)六氟磷酸脲
DMF:N,N-二甲基甲酰胺;TEA:三乙胺;DIPEA:二异丙基乙基胺
DMAC:N,N-二甲基乙酰胺;Pd(dppf)Cl
2:[1,1'-双(二苯基膦基)二茂铁]二氯化钯
NBS:N-溴代丁二酰亚胺;NMP:N-甲基吡咯烷酮;Pd(PPh
3)
4:四三苯基膦钯
DPPA:叠氮磷酸二苯酯;4-DMAP:4-二甲氨基吡啶;NaBH
3CN:氰基硼氢化钠
PTSA:对甲基苯磺酸;MeOH:甲醇;EtOH:乙醇;Boc
2O:二叔丁基二碳酸酯
DMSO:二甲基亚砜;Pd(dppf)Cl
2:[1,1'-双(二苯基膦基)二茂铁]二氯化钯
实施例1:
将30mg的(IM-1)、35mg的(Acid-1)和78mg的N,N,N′,N′-四甲基-O-(7-氮杂苯并***-1-基)六氟磷酸脲(HATU,CAS:148893-10-1)溶于3mL的N,N-二甲基甲酰胺(DMF)中,搅拌下加入50μL二异丙基乙基胺(DIPEA),而后于室温搅拌12小时。将反应混合物倾入到水中,乙酸乙酯萃取三次,合并乙酸乙酯层,用饱和氯化钠洗涤五次,最后有机相经无水硫酸钠干燥后浓缩,经制备薄层层析纯化得I-1,产量:47mg,产率:92.1%。
1H NMR(400MHz,Chloroform-d)δ11.02(d,J=7.3Hz,1H),8.80–8.74(m,1H),8.56(dd,J=4.9,1.7Hz,1H),8.34(s,1H),7.82(dt,J=7.9,2.0Hz,1H),7.53(dt,J=5.2,1.9Hz,3H),7.41(d,J=2.0Hz,1H),7.37(dd,J=8.2,1.9Hz,1H),7.33–7.28(m,1H),7.27(s,1H),7.25(d,J=3.3Hz,1H),7.17(d,J=8.2Hz,1H),6.54(d,J=0.9Hz,1H),5.14(dt,J=11.3,7.2Hz,1H), 4.68(dd,J=9.7,7.3Hz,1H),4.40(dd,J=11.4,9.7Hz,1H),3.45(s,3H),2.05(s,3H).LC-MS:505.3.[M+H]
+
使用相同的合成方法,以不同的氨基化合物和羧基化合物为起始原料,获得以下化合物:
实验例2:化合物分子水平对RIPK1激酶活性的影响
384孔板中,加入2μL酶和1μL不同浓度化合物,同时设置不加激酶和化合物的0%激酶活性对照孔和不加化合物的100%激酶活性对照孔,室温孵育10min。继续加入2μL ATP+底物肽段的混合液(底物终浓度100μg/mL,ATP终浓度10μM),37℃孵育1h。每孔加入5μL ADP-Glo
TMReagent,室温孵育40分钟,去除未反应ATP。每孔加入10μL Kinase Detection Reagent,室温孵育30-60分钟,使反应中生成的ADP转化为ATP。检测荧光信号(luminescence:integration time 0.5s)。通过平均RLU值表示0%激酶活性(无酶和化合物)和100%激酶活性(无化合物)来计算每个孔的抑制率,IC
50值采用GraphPad Prism软件计算求得。
表1:化合物对RIPK1酶抑制活性
编号 | IC 50 | 编号 | IC 50 |
I-1 | + | II-4 | + |
II-1 | + | II-5 | + |
I-2 | + | II-6 | + |
I-5 | + | II-11 | + |
I-6 | + | II-12 | + |
I-11 | + | II-13 | + |
I-12 | + | II-14 | + |
II-2 | + | II-15 | + |
II-3 | + | II-16 | + |
其中,+表示IC
50小于(≤)0.1μM,从表1可以看出,本发明化合物对RIPK1酶具有明显的抑制作用。
实验例3:化合物对I2.1细胞程序性坏死回复作用
测试I2.1细胞株(人源急性T细胞白血病Jurkat细胞的FADD突变体,细胞中FADD蛋白缺失,单独TNFα即可诱导细胞发生程序性坏死)。以CCK-8细胞计数试剂盒(Dojindo)检测。
处于对数生长期的I2.1细胞按合适密度接种至96孔培养板中,培养过夜后,先加入不同浓度的化合物,一小时之后加入20ng/mL的TNFα刺激,并设定不加化合物不加刺激因 子对照孔(阳性对照)和不加化合物加刺激因子对照孔(阴性对照)。待化合物作用细胞24h后,化合物对细胞增殖的影响采用CCK-8细胞计数试剂盒(Dojindo)检测,每孔加入10μL CCK-8试剂,置于37℃培养箱中放置2-4小时后,用全波长式微孔板酶标仪SpectraMax190读数,测定波长为450nm。
采用以下列公式计算化合物对细胞程序性坏死的回复率(%):
回复率(%)=(OD给药孔-OD阴性对照孔)/(OD阳性对照孔-OD阴性对照孔)×100%
IC
50值采用GraphPad Prism软件计算求得。
表2:化合物对I2.1细胞死亡的回复率
其中,“+”表示IC
50小于(≤)1μM;“-”表示IC
50大于(>)1μM
从上述试验结果可以看出,相对于“对比化合物1”,本发明化合物对于TNFα诱导的Hepa1-6细胞死亡具有明显回复作用。
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
Claims (10)
- 一种通式(I)所示的化合物或其立体异构体、对映异构体、非对映异构体、阻转异构体、光学异构体、外消旋体、互变异构体或其药学上可接受的盐、其前药、其水合物或溶剂合物、其经同位素标记之化合物,其中,Cy 1选自下组:R 5在每次出现时独立地选自:H、D、卤素、CD 3、C1-C8烷基、卤代C1-C8烷基、C1-C8烷氧基、卤代C1-C8烷氧基、氰基、氨基、C1-C8烷基取代的氨基、羟基、巯基、C1-C8烷基硫基;Cy 2选自被0-5个R 8取代的以下基团:C3-C14环烷基、C6-C14元芳基、6-14元杂芳基、或3-14元杂环基;R 4在每次出现时独立地选自:H、D、CH 3、CD 3;各虚线独立地表示单键或双键;Z 1选自:O、S、N、C=O、SO、SO 2、NH;Z 2选自C(R z2) 2、N、CR z2;各R z2独立地为H、卤素、羟基、任选取代的C1-C8烷基,或者两个R z2与它们所连接的碳原子一起形成任选取代的C3-C6碳环或3-6元杂环;Z 3、Z 4选自C、CH、N;环A为C6-C14元芳环、5元杂芳环、6-14元杂芳环、C3-C14碳环或3-14元杂环;m选自1、2、3、4;R 1在每次出现时独立地选自H、D、“R 7-C≡C-”、R 1a;较佳地环A上至少有一个R 1为“R 7-C≡C-”的取代基;R 1a、R 7在每次出现时独立地为由0-5个R 1a2取代的R 1a1;R 1a1、R 1a2可选被0-5个R 1a3取代;R 1a3为“-Linker2-R 1a4”;Linker2不存在,或者Linker2选自:键、O、NH、NR 1a4、-C(=O)O-、-C(=O)NH-、-C(=O)NR 1a4-、3-14元环烷基、3-14元杂环基、C6-C14芳基、5-14元杂芳基;R 2不存在,或者R 2在Z 4的邻位,且与R 3及它们所连接的原子一起形成任选取代或未取代的的5-6元杂环;R 3选自:H、D、CH 3、CD 3;Y为O、S、NR y,其中R y和R 3与它们所连接的原子一起形成任选取代的5-6元杂环或5-6元杂芳环;R 6选自:CD 3、C1-C8烷基、卤代C1-C8烷基、C6-C14芳基;R 8在每次出现时独立地选自:H、D、卤素、CD 3、C1-C8烷基、卤代C1-C8烷基、C1-C8烷氧基、卤代C1-C8烷氧基、氰基、氨基、C1-C8烷基取代的氨基、羟基、巯基、C1-C8烷基硫基、卤代C1-C8烷基硫基、-C(=O)NH2、-C(=O)NH(C1-C8烷基)、-C(=O)-(C1-C8烷基)、氧代、硫代;R 1a1、R 1a2在每次出现独立地选自下组:H、D、卤素、C1-C8烷基、卤代C1-C8烷基、C1-C8烷氧基、卤代的C1-C8烷氧基、C1-C6烷氧基取代的C1-C6烷氧基、C2-C8烯基、卤代C2-C8烯基、C2-C8烯基氧基、卤代C2-C8烯基氧基、C2-C8炔基、卤代C2-C8炔基、C2-C8炔基氧基、卤代C2-C8炔基氧基、C3-C14环烷基、(C3-C14环烷基)-(C1-C8烷基)-、(C3-C14环烷基)氧基、(C3-C14环烷基)-(C1-C8烷基)氧基、(C3-C14环烷基)氧基(C1-C8烷基)-、(C3-C14环烷基)硫基、(C3-C14环烷基)-(C1-C8烷基)硫基、(C3-C14环烷基)硫基(C1-C8烷基)-、(C3-C14环烷基)NH-、(C3-C14环烷基)-(C1-C8烷基)-NH-、(C3-C14环烷基)-NH-(C1-C8烷基)-、(C3-C14环烷基)-C(=O)-、(C3-C14环烷基)-(C1-C8烷基)-C(=O)-、(C3-C14环烷基)C(=O)-(C1-C8烷基)-、(C3-C14环烷基)-C(=O)O-、(C3-C14环烷基)-(C1-C8烷基)-C(=O)O-、(C3-C14环烷基)-C(=O)O-(C1-C8烷基)-、(C3-C14环烷基)-OC(=O)-、(C3-C14环烷基)-(C1-C8烷基)-OC(=O)-、(C3-C14环烷基)-OC(=O)-(C1-C8烷基)-、(C3-C14环烷基)-C(=O)NH-、(C3-C14环烷基)-(C1-C8烷基)-C(=O)NH-、(C3-C14环烷基)-C(=O)NH-(C1-C8烷基)-、(C3-C14环烷基)-NHC(=O)-、(C3-C14环烷基)-(C1-C8烷基)-NHC(=O)-、(C3-C14环烷基)-(C1-C8烷基)-NHC(=O)-、(C1-C8烷基)-(C3-C14环烷基)-、羟基(C3-C14环烷基)-、(C1-C8烷氧基)-(C3-C14环烷基)-、羟基(C1-C8烷基)-(C3-C14环烷基)-、巯基(C3-C14环烷基)、(C1-C8烷硫基)-(C3-C14环烷基)-、巯基(C1-C8烷基)-(C3-C14环烷基)-、氨基(C3-C14环烷基)、(C1-C8烷基)NH-(C3-C14环烷基)-、氨基(C1-C8烷基)-(C3-C14环烷基)-、HC(=O)-(C3-C14环烷基)-、(C1-C8烷基)-C(=O)-(C3-C14环烷基)-、HC(=O)-(C1-C8烷基)-(C3-C14环烷基)-、 HC(=O)O-(C3-C14环烷基)-、(C1-C8烷基)-C(=O)O-(C3-C14环烷基)-、HC(=O)O-(C1-C8烷基)-(C3-C14环烷基)-、HOC(=O)-(C3-C14环烷基)-、(C1-C8烷基)-O-C(=O)-(C3-C14环烷基)-、HO-C(=O)-(C1-C8烷基)-(C3-C14环烷基)-、HC(=O)NH-(C3-C14环烷基)-、(C1-C8烷基)C(=O)NH-(C3-C14环烷基)-、HC(=O)NH-(C1-C8烷基)-(C3-C14环烷基)-、NH 2C(=O)-(C3-C14环烷基)-、(C1-C8烷基)NHC(=O)-(C3-C14环烷基)-、NH 2C(=O)-(C1-C8烷基)-(C3-C14环烷基)-、(C1-C8烷基)-(C3-C14环烷基)-(C1-C8烷基)-、3-14元杂环基、(3-14元杂环基)-(C1-C8烷基)-、(3-14元杂环基)氧基、(3-14元杂环基)-(C1-C8烷基)-氧基、(3-14元杂环基)氧基-(C1-C8烷基)-、(3-14元杂环基)硫基、(3-14元杂环基)-(C1-C8烷基)-硫基、(3-14元杂环基)硫基-(C1-C8烷基)-、(3-14元杂环基)NH-、(3-14元杂环基)(C1-C8烷基)NH-、(3-14元杂环基)-NH-(C1-C8烷基)-、(3-14元杂环基)-C(=O)-、(3-14元杂环基)-(C1-C8烷基)-C(=O)-、(3-14元杂环基)-C(=O)-(C1-C8烷基)-、(3-14元杂环基)-C(=O)O-、(3-14元杂环基)-(C1-C8烷基)-C(=O)O-、(3-14元杂环基)-C(=O)O-(C1-C8烷基)-、(3-14元杂环基)-OC(=O)-、(3-14元杂环基)-(C1-C8烷基)-OC(=O)-、(3-14元杂环基)-OC(=O)-(C1-C8烷基)-、(3-14元杂环基)-C(=O)NH-、(3-14元杂环基)-(C1-C8烷基)-C(=O)NH-、(3-14元杂环基)-C(=O)NH-(C1-C8烷基)-、(3-14元杂环基)-NHC(=O)-、(3-14元杂环基)-(C1-C8烷基)-NHC(=O)-、(3-14元杂环基)-NHC(=O)-(C1-C8烷基)-、(C1-C8烷基)-(3-14元杂环基)-、羟基(3-14元杂环基)-、(C1-C8烷氧基)-(3-14元杂环基)-、羟基(C1-C8烷基)-(3-14元杂环基)-、巯基(C3-C14环烷基)、(C1-C8烷硫基)-(3-14元杂环基)-、巯基(C1-C8烷基)-(3-14元杂环基)-、氨基(3-14元杂环基)、(C1-C8烷基)NH-(3-14元杂环基)-、氨基(C1-C8烷基)-(3-14元杂环基)-、HC(=O)-(3-14元杂环基)-、(C1-C8烷基)-C(=O)-(3-14元杂环基)-、HC(=O)-(C1-C8烷基)-(3-14元杂环基)-、HC(=O)O-(3-14元杂环基)-、(C1-C8烷基)-C(=O)O-(3-14元杂环基)-、HC(=O)O-(C1-C8烷基)-(3-14元杂环基)-、HOC(=O)-(3-14元杂环基)-、(C1-C8烷基)-O-C(=O)-(3-14元杂环基)-、HO-C(=O)-(C1-C8烷基)-(3-14元杂环基)-、HC(=O)NH-(3-14元杂环基)-、(C1-C8烷基)C(=O)NH-(3-14元杂环基)-、HC(=O)NH-(C1-C8烷基)-(3-14元杂环基)-、NH 2C(=O)-(3-14元杂环基)-、(C1-C8烷基)NHC(=O)-(3-14元杂环基)-、NH 2C(=O)-(C1-C8烷基)-(3-14元杂环基)-、(C1-C8烷基)-(3-14元杂环基)-(C1-C8烷基)-、C6-C14芳基、(C6-C14芳基)-(C1-C8烷基)-、(C6-C14芳基)氧基、(C6-C14芳基)-(C1-C8烷基)氧基、(C6-C14芳基)氧基(C1-C8烷基)-、(C6-C14芳基)硫基、(C6-C14芳基)-(C1-C8烷基)硫基、(C6-C14芳基)硫基(C1-C8烷基)-、(C6-C14芳基)NH-、(C6-C14芳基)-(C1-C8烷基)-NH-、(C6-C14芳基)-NH-(C1-C8烷基)-、(C6-C14芳基)-C(=O)-、(C6-C14芳基)-(C1-C8烷基)-C(=O)-、(C6-C14芳基)C(=O)-(C1-C8烷基)-、(C6-C14芳基)-C(=O)O-、(C6-C14芳基)-(C1-C8烷基)-C(=O)O-、(C6-C14芳基)-C(=O)O-(C1-C8烷基)-、(C6-C14芳基)-OC(=O)-、(C6-C14芳基)-(C1-C8烷基)-OC(=O)-、(C6-C14芳基)-OC(=O)-(C1-C8烷基)-、(C6-C14芳基)-C(=O)NH-、(C6-C14芳基)-(C1-C8烷基)-C(=O)NH-、(C6-C14芳基)-C(=O)NH-(C1-C8烷基)-、(C6-C14芳基)-NHC(=O)-、(C6-C14芳基)-(C1-C8烷基)-NHC(=O)-、(C6-C14芳基)-(C1-C8烷基)-NHC(=O)-、(C1-C8烷基)-(C6-C14芳基)-、羟基(C6-C14芳基)-、(C1-C8烷氧基)-(C6-C14芳基)-、羟基(C1-C8烷基)-(C6-C14芳基)-、巯基(C3-C14环烷基)、(C1-C8烷硫基)-(C6-C14 芳基)-、巯基(C1-C8烷基)-(C6-C14芳基)-、氨基(C6-C14芳基)、(C1-C8烷基)NH-(C6-C14芳基)-、氨基(C1-C8烷基)-(C6-C14芳基)-、HC(=O)-(C6-C14芳基)-、(C1-C8烷基)-C(=O)-(C6-C14芳基)-、HC(=O)-(C1-C8烷基)-(C6-C14芳基)-、HC(=O)O-(C6-C14芳基)-、(C1-C8烷基)-C(=O)O-(C6-C14芳基)-、HC(=O)O-(C1-C8烷基)-(C6-C14芳基)-、HOC(=O)-(C6-C14芳基)-、(C1-C8烷基)-O-C(=O)-(C6-C14芳基)-、HO-C(=O)-(C1-C8烷基)-(C6-C14芳基)-、HC(=O)NH-(C6-C14芳基)-、(C1-C8烷基)C(=O)NH-(C6-C14芳基)-、HC(=O)NH-(C1-C8烷基)-(C6-C14芳基)-、NH 2C(=O)-(C6-C14芳基)-、(C1-C8烷基)NHC(=O)-(C6-C14芳基)-、NH 2C(=O)-(C1-C8烷基)-(C6-C14芳基)-、(C1-C8烷基)-(C6-C14芳基)-(C1-C8烷基)-、5-14元杂芳基、(5-14元杂芳基)-(C1-C8烷基)-、(5-14元杂芳基)氧基、(5-14元杂芳基)-(C1-C8烷基)氧基、(5-14元杂芳基)氧基(C1-C8烷基)-、(5-14元杂芳基)硫基、(5-14元杂芳基)-(C1-C8烷基)硫基、(5-14元杂芳基)硫基(C1-C8烷基)-、(5-14元杂芳基)NH-、(5-14元杂芳基)-(C1-C8烷基)-NH-、(5-14元杂芳基)-NH-(C1-C8烷基)-、(5-14元杂芳基)-C(=O)-、(5-14元杂芳基)-(C1-C8烷基)-C(=O)-、(5-14元杂芳基)C(=O)-(C1-C8烷基)-、(5-14元杂芳基)-C(=O)O-、(5-14元杂芳基)-(C1-C8烷基)-C(=O)O-、(5-14元杂芳基)-C(=O)O-(C1-C8烷基)-、(5-14元杂芳基)-OC(=O)-、(5-14元杂芳基)-(C1-C8烷基)-OC(=O)-、(5-14元杂芳基)-OC(=O)-(C1-C8烷基)-、(5-14元杂芳基)-C(=O)NH-、(5-14元杂芳基)-(C1-C8烷基)-C(=O)NH-、(5-14元杂芳基)-C(=O)NH-(C1-C8烷基)-、(5-14元杂芳基)-NHC(=O)-、(5-14元杂芳基)-(C1-C8烷基)-NHC(=O)-、(5-14元杂芳基)-(C1-C8烷基)-NHC(=O)-、(C1-C8烷基)-(5-14元杂芳基)-、羟基(5-14元杂芳基)-、(C1-C8烷氧基)-(5-14元杂芳基)-、羟基(C1-C8烷基)-(5-14元杂芳基)-、巯基(C3-C14环烷基)、(C1-C8烷硫基)-(5-14元杂芳基)-、巯基(C1-C8烷基)-(5-14元杂芳基)-、氨基(5-14元杂芳基)、(C1-C8烷基)NH-(5-14元杂芳基)-、氨基(C1-C8烷基)-(5-14元杂芳基)-、HC(=O)-(5-14元杂芳基)-、(C1-C8烷基)-C(=O)-(5-14元杂芳基)-、HC(=O)-(C1-C8烷基)-(5-14元杂芳基)-、HC(=O)O-(5-14元杂芳基)-、(C1-C8烷基)-C(=O)O-(5-14元杂芳基)-、HC(=O)O-(C1-C8烷基)-(5-14元杂芳基)-、HOC(=O)-(5-14元杂芳基)-、(C1-C8烷基)-O-C(=O)-(5-14元杂芳基)-、HO-C(=O)-(C1-C8烷基)-(5-14元杂芳基)-、HC(=O)NH-(5-14元杂芳基)-、(C1-C8烷基)C(=O)NH-(5-14元杂芳基)-、HC(=O)NH-(C1-C8烷基)-(5-14元杂芳基)-、NH 2C(=O)-(5-14元杂芳基)-、(C1-C8烷基)NHC(=O)-(5-14元杂芳基)-、NH 2C(=O)-(C1-C8烷基)-(5-14元杂芳基)-、(C1-C8烷基)-(5-14元杂芳基)-(C1-C8烷基)-、羟基、羟基取代的C1-C8烷基、巯基、巯基取代的C1-C8烷基、氨基、氨基取代的C1-C8烷基、-NH(C1-C8烷基)、-N(C1-C8烷基)(C1-C8烷基)、氰基、氰基取代的C1-C8烷基、-COOH、-(C1-C8烷基)-COOH、-C(=O)O-(C1-C8烷基)、-(C1-C8烷基)-C(=O)O-(C1-C8烷基)、-OC(=O)H、-(C1-C8烷基)-OC(=O)H、-OC(=O)-(C1-C8烷基)、-(C1-C8烷基)-OC(=O)-(C1-C8烷基)、-C(O)H、-(C1-C8烷基)-C(=O)H、-C(=O)-(C1-C8烷基)、-(C1-C8烷基)-C(=O)-(C1-C8烷基)、NH 2C(=O)-、一个或二个C1-C8烷基取代的NH 2C(O)-、一个或二个C1-C8环烷基取代的NH 2C(O)-、一个或二个C6-C14芳基取代的NH 2C(O)-、一个或二个5-14元杂芳基取代的NH 2C(O)-、一个或二个4-10元杂环基取代的NH 2C(O)-、NH 2C(=O)-(C1-C8烷基)-、一个或二个C1-C8烷基取代的NH 2C(O)-(C1-C8烷基)-、一个或二 个C1-C8环烷基取代的NH 2C(O)-(C1-C8烷基)-、一个或二个C6-C14芳基取代的NH 2C(O)-(C1-C8烷基)-、一个或二个5-14元杂芳基取代的NH 2C(O)-(C1-C8烷基)-、一个或二个4-10元杂环基取代的NH 2C(O)-(C1-C8烷基)-、氧代(=O)、硫代(=S);R 1a4在每次出现时独立地选自下组:H、D、卤素、羟基、C1-C8烷基、卤代C1-C8烷基、C2-C8烯基、卤代C2-C8烯基、C2-C8炔基、卤代C2-C8炔基、(C1-C15烷基)-OC(=O)-、(C6-C14芳基)-OC(=O)-、(4-12元杂环基)-OC(=O)-、(5-14元杂芳基)-OC(=O)-、(C1-C15烷基)-C(=O)-、(C6-C14芳基)-C(=O)-、(4-12元杂环基)-C(=O)-、(5-14元杂芳基)-C(=O)-、(C1-C15烷基)-C(=O)O-、(C6-C14芳基)-C(=O)O-、(4-12元杂环基)-C(=O)O-、(5-14元杂芳基)-C(=O)O-、(卤代C1-C15烷基)-OC(=O)-、(卤代C6-C14芳基)-OC(=O)-、(卤代4-12元杂环基)-OC(=O)-、(卤代5-14元杂芳基)-OC(=O)-、(卤代C1-C15烷基)-C(=O)-、(卤代C6-C14芳基)-C(=O)-、(卤代4-12元杂环基)-C(=O)-、(卤代5-14元杂芳基)-C(=O)-、(卤代C1-C15烷基)-C(=O)O-、(卤代C6-C14芳基)-C(=O)O-、(卤代4-12元杂环基)-C(=O)O-、(卤代5-14元杂芳基)-C(=O)O-、C1-C8烷基取代的(C1-C15烷基)-OC(=O)-、C1-C8烷基取代的(C6-C14芳基)-OC(=O)-、C1-C8烷基取代的(4-12元杂环基)-OC(=O)-、C1-C8烷基取代的(5-14元杂芳基)-OC(=O)-、C1-C8烷基取代的(C1-C15烷基)-C(=O)-、C1-C8烷基取代的(C6-C14芳基)-C(=O)-、C1-C8烷基取代的(4-12元杂环基)-C(=O)-、C1-C8烷基取代的(5-14元杂芳基)-C(=O)-、C1-C8烷基取代的(C1-C15烷基)-C(=O)O-、C1-C8烷基取代的(C6-C14芳基)-C(=O)O-、C1-C8烷基取代的(4-12元杂环基)-C(=O)O-、C1-C8烷基取代的(5-14元杂芳基)-C(=O)O-、(C1-C8烷基) 3-Si-(C1-C8烷基)-O-(C1-C8亚烷基)-、被卤素取代或未取代的(C1-C8烷基)-OC(=O)-(C1-C8烷基)C(=O)O-、被卤素取代或未取代的(C1-C8烷基)-OC(=O)-(C3-C14环烷基)C(=O)O-、糖基、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(NH-(C1-C8烷基)C(=O)O(C1-C8烷基))、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(O-(C1-C8烷基)C(=O)O(C1-C8烷基))、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(NH-(C1-C8烷基)OC(=O)(C1-C8烷基))、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(O-(C1-C8烷基)OC(=O)(C1-C8烷基))、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(NH-(C1-C8烷基)-S-C(=O)(C1-C8烷基))、-O-P(=O)(O-卤代或未卤代的C6-C14芳基)(O-(C1-C8烷基)-S-C(=O)(C1-C8烷基))、-O-P(=O)(ONa) 2、-O-P(=O)(OK) 2、-O-P(=O)(OLi) 2、-O-(卤代或未卤代的C1-C8烷基)-P(=O)(O-C1-C8烷基) 2、(C1-C8烷基)-C(=O)-CH=CH-、氨基酸酰基、C1-C16烷基、卤代C1-C16烷基、C6-C14芳基、卤代C6-C14芳基。
- 一种药物组合物,其特征在于,包含:药学上可接受的载体和一种或多种权利要求1-5中任意一项所述的化合物或其立体异构体、对映异构体、非对映异构体、阻转异构体、光学异构体、外消旋体、互变异构体或其药学上可接受的盐、其前药、其水合物或溶剂合物、其经同位素标记之化合物。
- 一种受体相互作用蛋白激酶1(RIPK1)抑制剂,其特征在于,包含一种或多种权利要求1-5中任意一项所述的化合物或其立体异构体、几何异构体、互变异构体、其药学上可接受的盐、其前药、其水合物或溶剂合物,或根据权利要求7所述的药物组合物。
- 一种权利要求1-5中任一项所述化合物或其立体异构体、对映异构体、非对映异构体、阻转异构体、光学异构体、外消旋体、互变异构体或其药学上可接受的盐、其前药、其水合物或溶剂合物、其经同位素标记之化合物或根据权利要求7所述的药物组合物的用途,其特征在于,用于制备药物,所述药物用于:1)检测和/或预防和/或治疗激酶相关疾病;2)检测和/或预防和/或治疗免疫、炎症和/或感染相关疾病;3)检测和/或预防和/或治疗缺血和/或再灌注损伤相关疾病;4)检测和/或预防和/或治疗退行性疾病;5)检测和/或预防和/或***相关疾病;6)检测和/或预防和/或治疗细胞坏死相关疾病;7)检测和/或预防和/或治疗代谢相关疾病;或者8)检测和/或预防和/或治疗眼部疾病。
- 一种权利要求1-5中任一项所述化合物或其立体异构体、对映异构体、非对映异构体、阻转异构体、光学异构体、外消旋体、互变异构体或其药学上可接受的盐、其前药、其水合物或溶剂合物、其经同位素标记之化合物或根据权利要求7所述的药物组合物的用途,其特征在于,用于制备检测和/或预防和/或治疗选自下组的疾病的药物:全身型幼年特发性关节炎,***,白细胞介素-1转化酶相关性发热综合征,败血症,斑秃,变应性疾病,过敏性疾病,乙型肝炎,丙型肝炎,多发性硬化,肺结节病,肺纤维化,肺炎,分枝杆菌感染,腹腔疾病,干燥综合征,骨关节炎,化脓性汗腺炎,坏死性小肠结肠炎,急性胰腺炎,脊柱关节炎,结肠炎,局限性回肠炎,抗磷脂综合征,克罗恩病,溃疡性肠炎,类风湿性关节炎,细菌感染,流感,慢性阻塞性肺病,病毒感染,脓毒症,皮炎,葡萄球菌感染,自身免疫疾病,全身性红斑狼疮,全身性炎症反应综合征,全身性硬皮病,朊病毒症,肾上腺皮质变性,肾炎,史-约综合征,手术感染,特应性皮炎,韦格纳肉芽肿,***性红斑狼疮,哮喘,新冠肺炎,血管炎,牙周炎,炎性肠病,胰腺炎,移植器官排除,银屑病,原发性硬化性胆管炎,肿瘤坏死因子受体相关周期性发热综合征,白细胞介素-1转换酶相关的发热综合征,自身免疫特发性血小板减少性紫癜,Fahr病,GM1神经节苷脂贮积病,GM2神经节苷脂贮积病,艾滋病相关痴呆综合征,Tau蛋白病,阿尔茨海默病,帕金森病,路易体痴呆,多***萎缩症,多重硬化,额颞叶痴呆,法伯病,弗里德赖希共济失调症,格林巴利综合征,亨廷顿病,原发性侧索硬化,肌萎缩性侧索硬化,脊髓性肌萎缩,假性延髓麻痹,进行性延髓麻痹,结节状硬化症,进行性核上性麻痹,进行性肌萎缩,精神***症,脱髓鞘病,慢性炎症性脱髓鞘性多发性神经病,尼曼匹克病,皮质基底节变性,溶酶体贮积病,桑德霍夫病,神经节细胞病,神经元蜡样脂褐质沉积症,术后认知障碍,双相障碍,糖尿病性神经病,疼痛(神经疼痛),谵妄,抑郁症,周围神经病变,自闭症,创伤,创伤性脑损伤,局部缺血,创伤性视网膜损伤,脑血管意外,脑卒中,地理性萎缩,对乙酰胺基酚中毒,急性肝衰竭,急性肾损伤,急性呼吸窘迫综合征,颅内出血,脑出血,脑缺血,缺血,缺血性损伤,缺氧性脑损伤,缺氧,烧伤,烧伤性休克,实体器官的缺血再灌注损伤,顺铂诱导的肾损伤,吸烟诱导的损伤,心肌梗塞,心力衰竭,中毒性表皮坏死松解症,急性肾小管坏死,心脏衰竭,NF-κB关键调节基因突变,白血病,髓细胞白血病,淋巴细胞白血病,T细胞白血病,淋巴瘤,T细胞淋巴瘤,鼻咽癌,表皮样癌,垂体腺瘤,胆道癌肉瘤,胆管癌,多发性骨髓瘤,儿童实体瘤,霍奇金病,非霍奇金淋巴瘤,非小细胞肺癌,小细胞肺癌,***区域癌,睾丸癌,***,子宫癌,子宫内膜癌,卵巢癌,骨癌,骨肉瘤,黑色素瘤,环境诱发的癌症,脊柱肿瘤,甲状腺癌,甲状旁腺癌,胶质母细胞瘤,结肠直肠癌,卡波西氏肉瘤,鳞状上皮细胞癌,脑胶质瘤,内分泌***癌症,尿道癌,膀胱癌,皮肤癌,皮肤或眼内恶性黑色素瘤,***癌,三阴性乳腺癌,神经胶质瘤,肾或输尿管癌,肾盂癌,肾上腺癌,实体器官恶性肿瘤,食道癌,输卵管癌,头和/或颈癌,外阴癌,胃癌,胃肠间质瘤,小肠癌,血液恶性肿瘤,胰腺癌,遗传性大动脉瘤,***癌,***癌,直肠癌,肿瘤血管生成,黄斑病 变,黄斑裂孔,黄斑毛细管扩张,干眼症,进行性视网膜萎缩,莱伯氏先天性黑蒙,囊性黄斑水肿,年龄相关性黄斑变性,青光眼,视网膜神经变性,缺血性视神经病变,缺血性视网膜疾病,糖尿病性视网膜病变,色素性视网膜炎,视网膜感光器疾病,视网膜退行性疾病,视神经疾病,视网膜脱离,医源性视网膜损伤,视网膜血管疾病,视锥视杆营养不良,无脉络膜症,眼底疾病,眼血管疾病,尤塞氏综合症,I型糖尿病,非酒精性脂肪肝,白癜风,唾液酸苷贮积症,肠易激综合征,达农病,胆固醇酯贮积症,沃尔曼病,低脂血症,动脉粥样硬化,多种硫酸酯酶缺乏症,法布里病,戈谢病,骨髓纤维化,骨质疏松症,胱氨酸贮积症,肌营养不良,多聚谷氨酰胺疾病,克拉伯病,慢性肾病,门克斯病,囊性纤维化病,庞皮病,泰伊-萨克斯二氏病,溶酶体酸脂酶缺乏,天冬氨酰葡萄糖胺尿症,痛风,威尔逊氏病,线粒体病症,岩藻糖苷贮积症,异染性脑白质营养不良,浴酶体酸脂酶缺乏,粘多糖累积病,粘脂质累积,致密性成骨不全症,血色病,Niemann-Pick病,Heme-氧化的IRP2泛素连接酶-1缺乏,骨坏死,链状泛素链组装复合物缺乏综合征,纤毛病等。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210072623 | 2022-01-21 | ||
CN202210072623.4 | 2022-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023138317A1 true WO2023138317A1 (zh) | 2023-07-27 |
Family
ID=87223793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/142343 WO2023138317A1 (zh) | 2022-01-21 | 2022-12-27 | 具有ripk1抑制活性的化合物、其制备方法及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116478150A (zh) |
WO (1) | WO2023138317A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020088194A1 (zh) * | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
CN111138448A (zh) * | 2018-11-02 | 2020-05-12 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
CN112368278A (zh) * | 2018-05-03 | 2021-02-12 | 里格尔药品股份有限公司 | Rip1抑制性化合物以及制备和使用其的方法 |
WO2021046382A1 (en) * | 2019-09-06 | 2021-03-11 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
WO2021046437A1 (en) * | 2019-09-06 | 2021-03-11 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
WO2021108198A1 (en) * | 2019-11-26 | 2021-06-03 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
WO2021203011A1 (en) * | 2020-04-02 | 2021-10-07 | Rigel Pharmaceuticals, Inc. | Rip1k inhibitors |
-
2022
- 2022-12-27 CN CN202211688025.6A patent/CN116478150A/zh active Pending
- 2022-12-27 WO PCT/CN2022/142343 patent/WO2023138317A1/zh unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112368278A (zh) * | 2018-05-03 | 2021-02-12 | 里格尔药品股份有限公司 | Rip1抑制性化合物以及制备和使用其的方法 |
WO2020088194A1 (zh) * | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
CN111138448A (zh) * | 2018-11-02 | 2020-05-12 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
WO2021046382A1 (en) * | 2019-09-06 | 2021-03-11 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
WO2021046437A1 (en) * | 2019-09-06 | 2021-03-11 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
WO2021108198A1 (en) * | 2019-11-26 | 2021-06-03 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
WO2021203011A1 (en) * | 2020-04-02 | 2021-10-07 | Rigel Pharmaceuticals, Inc. | Rip1k inhibitors |
US20210317135A1 (en) * | 2020-04-02 | 2021-10-14 | Rigel Pharmaceuticals, Inc. | Rip1k inhibitors |
Non-Patent Citations (2)
Title |
---|
DATABASE REGISTRY 22 June 2020 (2020-06-22), ANONYMOUS : "Benzamide, 3-cyclobutyl-N-(2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3 yl)-", XP093079226, retrieved from STN Database accession no. 2431871-28-0 * |
DATABASE REGISTRY 23 June 2020 (2020-06-23), ANONYMOUS : "Benzamide, 3-cyclopropyl-N-(2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepinyl)-", XP093079224, retrieved from STN Database accession no. 2432277-86-4 * |
Also Published As
Publication number | Publication date |
---|---|
CN116478150A (zh) | 2023-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7402685B2 (ja) | (s)-7-(1-アクリロイルピペリジン-4-イル)-2-(4-フェノキシフェニル)-4,5,6,7-テトラ-ヒドロピラゾロ[1,5-a]ピリミジン-3-カルボキサミドの結晶形、その調製、及びその使用 | |
AU2013299117B2 (en) | Piperazinotrizole compound, preparation method therefor, and use thereof in drug preparation | |
TW202128691A (zh) | Kras 突變蛋白抑制劑 | |
CA3147493A1 (en) | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors | |
CN109422733A (zh) | 一类抑制并降解酪氨酸蛋白激酶alk的化合物 | |
TW200914003A (en) | Imidazopyridinones | |
WO2010121486A1 (zh) | 基于吉西他滨结构的前药及其合成方法及应用 | |
CN107530350A (zh) | 细胞坏死抑制剂及相关方法 | |
TWI342309B (en) | Novel fused pyrrolocarbazoles | |
KR20120113760A (ko) | 정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법 | |
WO2019113523A1 (en) | Compounds and therapeutic uses thereof | |
EP3418277B1 (en) | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | |
CN109867675A (zh) | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 | |
TW202302587A (zh) | 異喹啉酮類化合物及其用途 | |
JP2016531947A (ja) | 配座固定されたPI3K及びmTOR阻害剤 | |
WO2023138317A1 (zh) | 具有ripk1抑制活性的化合物、其制备方法及其用途 | |
TW201400458A (zh) | (2-雜芳基胺基)琥珀酸衍生物 | |
WO2023138433A2 (zh) | 具有ripk1抑制活性的酰胺化合物、其制备方法及其用途 | |
CN113336774B (zh) | 作为trk抑制剂的取代的手性二芳基大环化合物 | |
KR102606167B1 (ko) | 불소 함유 치환 벤조티오펜 화합물, 그의 약학적 조성물 및 응용 | |
CN101220037B (zh) | 10-位取代高喜树碱类化合物及其用途 | |
CN110283174B (zh) | 一类PI3Kδ抑制剂及其用途 | |
US20100317650A1 (en) | Imidazopyridine derivatives useful as inos inhibitors | |
WO2022007841A1 (zh) | 一种egfr抑制剂、其制备方法和在药学上的应用 | |
WO2023109918A1 (zh) | 含氮杂环化合物、其制备方法及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22921738 Country of ref document: EP Kind code of ref document: A1 |